Kv11.1

1

Hirano-Iwata A et al. Reconstitution of Human Ion Channels into Solvent-free Lipid Bilayers Enhanced by Centrifugal Forces.
Biophys. J., 2016 May 24 , 110 (2207-15).

2

Hayashi S et al. Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
Eur J Med Chem, 2016 May 23 , 114 (345-64).

3

Zeng H et al. Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes.
J Pharmacol Toxicol Methods, 2016 May 21 , ().

4

Baczkó I et al. Rabbit models as tools for preclinical cardiac electrophysiological safety testing: Importance of repolarization reserve.
Prog. Biophys. Mol. Biol., 2016 May 18 , ().

5

Su Z et al. Novel cell-free high-throughput screening method for pharmacological tools targeting K+ channels.
Proc. Natl. Acad. Sci. U.S.A., 2016 May 17 , 113 (5748-53).

6

Perez-Neut M et al. Activation of hERG3 channel stimulates autophagy and promotes cellular senescence in melanoma.
Oncotarget, 2016 Mar 1 , ().

7

Osborne JD et al. Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
J. Med. Chem., 2016 Jun 9 , 59 (5221-37).

8

Zhang X et al. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
J Pharmacol Toxicol Methods, 2016 Jun 7 , ().

9

Colatsky T et al. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
J Pharmacol Toxicol Methods, 2016 Jun 6 , ().

10

Carbonell-Pascual B et al. Comparison between Hodgkin-Huxley and Markov formulations of cardiac ion channels.
J. Theor. Biol., 2016 Jun 21 , 399 (92-102).

11

Spence S et al. Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms.
Toxicol. Sci., 2016 Jun 2 , ().

12

Șterbuleac D et al. An antiarrhythmic agent as a promising lead compound for targeting the hEAG1 ion channel in cancer therapy: insights from molecular dynamics simulations.
Chem Biol Drug Des, 2016 Jun 2 , ().

13

Yamaguchi Y et al. Latent pathogenicity of the G38S polymorphism of KCNE1 K(+) channel modulator.
Heart Vessels, 2016 Jun 2 , ().

14

Ng CA et al. Tyrosine residues from the S4-S5 linker of Kv11.1 channels are critical for slow deactivation.
J. Biol. Chem., 2016 Jun 17 , ().

15

Major P et al. A novel transgenic rabbit model with reduced repolarization reserve: long QT syndrome caused by a dominant-negative mutation of the KCNE1 gene.
Br. J. Pharmacol., 2016 Jun , 173 (2046-61).

16

Wu W et al. Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology.
Card Electrophysiol Clin, 2016 Jun , 8 (275-84).

17

Van Driest SL et al. Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic Medical Records.
JAMA, 2016 Jan 5 , 315 (47-57).

18

Cheng J et al. Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.
J. Med. Chem., 2016 Jan 28 , 59 (578-91).

19

Lee S et al. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Toxicol. Appl. Pharmacol., 2016 Jan 25 , ().

20

Yu HB et al. Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay.
Acta Pharmacol. Sin., 2016 Jan , 37 (111-23).

21

Heide J et al. Differential Response to Risperidone in Schizophrenia Patients by KCNH2 Genotype and Drug Metabolizer Status.
Am J Psychiatry, 2016 Jan , 173 (53-9).

22

Bodi I et al. Mechanisms of acquired long-QT syndrome in patients with propionic acidemia.
Heart Rhythm, 2016 Feb 5 , ().

23

Neubauer J et al. Post-mortem whole-exome sequencing (WES) with a focus on cardiac disease-associated genes in five young sudden unexplained death (SUD) cases.
Int. J. Legal Med., 2016 Feb 4 , ().

24

Gintant G et al. Evolution of strategies to improve preclinical cardiac safety testing.
Nat Rev Drug Discov, 2016 Feb 19 , ().

25

Furtado MB et al. A novel conditional mouse model for Nkx2-5 reveals transcriptional regulation of cardiac ion channels.
Differentiation, 2016 Feb 17 , ().

26

Nozaki Y et al. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -Assessment of inter-facility and cells lot-to-lot-variability.
Regul. Toxicol. Pharmacol., 2016 Feb 13 , ().

27

Crottes D et al. SIGMAR1 Regulates Membrane Electrical Activity in Response to Extracellular Matrix Stimulation to Drive Cancer Cell Invasiveness.
Cancer Res., 2016 Feb 1 , 76 (607-18).

28

Fang P et al. [Progress in research on defective protein trafficking and functional restoration in HERG-associated long QT syndrome].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2016 Feb , 33 (101-4).

29

Crumb WJ et al. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
J Pharmacol Toxicol Methods, 2016 Apr 6 , ().

30

Marostica E et al. PK/PD Modelling of the QT Interval: a Step Towards Defining the Translational Relationship Between In Vitro, Awake Beagle Dogs, and Humans.
AAPS J, 2016 Apr 26 , ().

31

Liu F et al. Cotranslational association of mRNA encoding subunits of heteromeric ion channels.
Proc. Natl. Acad. Sci. U.S.A., 2016 Apr 26 , 113 (4859-64).

32

Atia J et al. Reconstruction of Cell Surface Densities of Ion Pumps, Exchangers, and Channels from mRNA Expression, Conductance Kinetics, Whole-Cell Calcium, and Current-Clamp Voltage Recordings, with an Application to Human Uterine Smooth Muscle Cells.
PLoS Comput. Biol., 2016 Apr , 12 (e1004828).

33

Ye F et al. The Scorpion Toxin Analogue BmKTX-D33H as a Potential Kv1.3 Channel-Selective Immunomodulator for Autoimmune Diseases.
Toxins (Basel), 2016 , 8 ().

34

Cubeddu LX Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.
Curr Cardiol Rev, 2016 , 12 (141-54).

35

Eng G et al. Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes.
Nat Commun, 2016 , 7 (10312).

36

Ichikawa M et al. Multigenerational Inheritance of Long QT Syndrome Type 2 in a Japanese Family.
Intern. Med., 2016 , 55 (259-62).

37

Zhao Y et al. Regulation of SCN3B/scn3b by Interleukin 2 (IL-2): IL-2 modulates SCN3B/scn3b transcript expression and increases sodium current in myocardial cells.
BMC Cardiovasc Disord, 2016 , 16 (1).

38

Hassinen M et al. Molecular basis and drug sensitivity of the delayed rectifier (IKr) in the fish heart.
Comp. Biochem. Physiol. C Toxicol. Pharmacol., 2015 Oct-Nov , 176-177 (44-51).

39

Arcangeli A et al. Novel perspectives in cancer therapy: Targeting ion channels.
Drug Resist. Updat., 2015 Jul-Aug , 21-22 (11-9).

40

Meedech P et al. Transmural dispersion of repolarization and cardiac remodeling in ventricles of rabbit with right ventricular hypertrophy.
J Pharmacol Toxicol Methods, 2015 Jan-Feb , 71 (129-36).

41

Hertz CL et al. Genetic investigations of sudden unexpected deaths in infancy using next-generation sequencing of 100 genes associated with cardiac diseases.
Eur. J. Hum. Genet., 2015 Sep 9 , ().

42

González Cabrera D et al. Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines.
J. Med. Chem., 2015 Sep 24 , 58 (7572-9).

43

Salmas RE et al. Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors.
Biophys. J., 2015 Sep 15 , 109 (1163-8).

44

Singh SB et al. Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6).
Bioorg. Med. Chem. Lett., 2015 Sep 1 , 25 (3636-43).

45

Singh SB et al. Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5).
Bioorg. Med. Chem. Lett., 2015 Sep 1 , 25 (3630-5).

46

Gupta N et al. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Cancer Chemother. Pharmacol., 2015 Sep , 76 (507-16).

47

Qu Y et al. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
Toxicol. Sci., 2015 Sep , 147 (286-95).

48

Farrugia A et al. Targeted next generation sequencing application in cardiac channelopathies: Analysis of a cohort of autopsy-negative sudden unexplained deaths.
Forensic Sci. Int., 2015 Sep , 254 (5-11).

49

Sheng R et al. Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.
ACS Chem Neurosci, 2015 Oct 19 , ().

50

Lees-Miller JP et al. In response to Melgari et al. "hERG potassium channel inhibition by ivabradine requires channel gating".
J. Mol. Cell. Cardiol., 2015 Oct , 87 (192-3).

51

Melgari D et al. hERG potassium channel inhibition by ivabradine requires channel gating.
J. Mol. Cell. Cardiol., 2015 Oct , 87 (126-8).

52

Frea S et al. New echocardiographic insights in short QT syndrome: More than a channelopathy?
Heart Rhythm, 2015 Oct , 12 (2096-105).

53

Lee HJ et al. Mechanism of inhibition by olanzapine of cloned hERG potassium channels.
Neurosci. Lett., 2015 Nov 16 , 609 (97-102).

54

Kang Y et al. Regulation of the human ether-a-go-go-related gene (hERG) potassium channel by Nedd4 family interacting proteins (Ndfips).
Biochem. J., 2015 Nov 15 , 472 (71-82).

55

Le Manach C et al. A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
J. Med. Chem., 2015 Nov 12 , 58 (8713-22).

56

Zhao H et al. Discovery of novel N-aryl piperazine CXCR4 antagonists.
Bioorg. Med. Chem. Lett., 2015 Nov 1 , 25 (4950-5).

57

Delaunois A et al. Cardiac safety of lacosamide: the non-clinical perspective.
Acta Neurol. Scand., 2015 Nov , 132 (337-45).

58

Xie S et al. Hypaconitine-induced QT prolongation mediated through inhibition of KCNH2 (hERG) potassium channels in conscious dogs.
J Ethnopharmacol, 2015 May 26 , 166 (375-9).

59

Hu N et al. High-performance beating pattern function of human induced pluripotent stem cell-derived cardiomyocyte-based biosensors for hERG inhibition recognition.
Biosens Bioelectron, 2015 May 15 , 67 (146-53).

60

Jin SS et al. Antiarrhythmic ionic mechanism of Guanfu base A--Selective inhibition of late sodium current in isolated ventricular myocytes from guinea pigs.
Chin J Nat Med, 2015 May , 13 (361-7).

61

Matus M et al. Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat.
Mol. Cell. Biochem., 2015 May , 403 (199-208).

62

Leren IS et al. Cardiac Mechanical Alterations and Genotype Specific Differences in Subjects With Long QT Syndrome.
JACC Cardiovasc Imaging, 2015 May , 8 (501-10).

63

Pires NM et al. Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor.
Eur. J. Pharmacol., 2015 Mar 5 , 750 (98-107).

64

Kolder IC et al. Analysis for Genetic Modifiers of Disease Severity in Patients with Long QT Syndrome Type 2.
Circ Cardiovasc Genet, 2015 Mar 3 , ().

65

Liu Z et al. Fluorogenic probe for the human Ether-a-Go-Go-Related Gene potassium channel imaging.
Anal. Chem., 2015 Mar 3 , 87 (2550-4).

66

Perry MD et al. Getting to the heart of hERG K(+) channel gating.
J. Physiol. (Lond.), 2015 Mar 27 , ().

67

Muñoz-Esparza C et al. Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing.
Rev Esp Cardiol (Engl Ed), 2015 Mar 25 , ().

68

Goodchild SJ et al. Sequence of gating charge movement and pore gating in HERG activation and deactivation pathways.
Biophys. J., 2015 Mar 24 , 108 (1435-47).

69

Perissinotti LL et al. Kinetic model for NS1643 drug activation of WT and L529I variants of Kv11.1 (hERG1) potassium channel.
Biophys. J., 2015 Mar 24 , 108 (1414-24).

70

Guo J et al. NS1643 interacts around L529 of hERG to alter voltage sensor movement on the path to activation.
Biophys. J., 2015 Mar 24 , 108 (1400-13).

71

Biliczki P et al. The interaction between delayed rectifier channel alpha-subunits does not involve hetero-tetramer formation.
Naunyn Schmiedebergs Arch. Pharmacol., 2015 Mar 20 , ().

72

Lastraioli E et al. hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.
Br. J. Cancer, 2015 Mar 17 , 112 (1076-87).

73

Villoutreix BO et al. Computational investigations of hERG channel blockers: New insights and current predictive models.
Adv. Drug Deliv. Rev., 2015 Mar 12 , ().

74

Ivanov SM et al. Identification of drug targets related to the induction of ventricular tachyarrhythmia through a systems chemical biology approach.
Toxicol. Sci., 2015 Mar 12 , ().

75

Yang L et al. Intravenous anesthetic propofol inhibits multiple human cardiac potassium channels.
Anesthesiology, 2015 Mar , 122 (571-84).

76

Han SN et al. [Effects of midazolam on hERG K+ channel].
Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2015 Mar , 31 (143-7).

77

Hayashi K et al. Functional Characterization of Rare Variants Implicated in Susceptibility to Lone Atrial Fibrillation.
Circ Arrhythm Electrophysiol, 2015 Jun 30 , ().

78

Zhou FJ et al. Two New Classes of T-Type Calcium Channel Inhibitors with New Chemical Scaffolds from Ganoderma cochlear.
Org. Lett., 2015 Jun 19 , 17 (3082-5).

79

Salmas RE et al. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
J Enzyme Inhib Med Chem, 2015 Jun 17 , (1-9).

80

Grienke U et al. Human Ether-à-go-go Related Gene (hERG) Channel Blocking Aporphine Alkaloids from Lotus Leaves and Their Quantitative Analysis in Dietary Weight Loss Supplements.
J. Agric. Food Chem., 2015 Jun 17 , 63 (5634-9).

81

Ai Y et al. Synthesis and Biological Evaluation of Novel Olean-28,13β-lactams as Potential Antiprostate Cancer Agents.
J. Med. Chem., 2015 Jun 11 , 58 (4506-20).

82

Wu W et al. The Link between Inactivation and High-Affinity Block of hERG1 Channels.
Mol. Pharmacol., 2015 Jun , 87 (1042-50).

83

Kurokawa J et al. Aromatase knockout mice reveal an impact of estrogen on drug-induced alternation of murine electrocardiography parameters.
J Toxicol Sci, 2015 Jun , 40 (339-48).

84

Zhao X et al. Up-regulation of miR-21 and miR-23a Contributes to As2 O3 -induced hERG Channel Deficiency.
Basic Clin. Pharmacol. Toxicol., 2015 Jun , 116 (516-23).

85

Schroder EA et al. The cardiomyocyte molecular clock regulates the circadian expression of Kcnh2 and contributes to ventricular repolarization.
Heart Rhythm, 2015 Jun , 12 (1306-14).

86

Yang LZ et al. Urocortin2 prolongs action potential duration and modulates potassium currents in guinea pig myocytes and HEK293 cells.
Eur. J. Pharmacol., 2015 Jul 5 , 758 (97-106).

87

Stattin EL et al. Genetic screening in sudden cardiac death in the young can save future lives.
Int. J. Legal Med., 2015 Jul 31 , ().

88

Zhang W et al. Kcnh2 and Kcnj8 Interactively Regulate Skin Wound Healing and Regeneration.
Wound Repair Regen, 2015 Jul 28 , ().

89

Yue Y et al. Pathogenesis of the Novel Autoimmune-Associated Long-QT Syndrome.
Circulation, 2015 Jul 28 , 132 (230-40).

90

De Mieri M et al. hERG Channel Inhibitory Daphnane Diterpenoid Orthoesters and Polycephalones A and B with Unprecedented Skeletons from Gnidia polycephala.
J. Nat. Prod., 2015 Jul 24 , 78 (1697-707).

91

Lee S et al. Cellular mechanisms for trazodone-induced cardiotoxicity.
Hum Exp Toxicol, 2015 Jul 17 , ().

92

Fermini B et al. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
J Biomol Screen, 2015 Jul 13 , ().

93

Harrell DT et al. Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome.
Int. J. Cardiol., 2015 Jul 1 , 190 (393-402).

94

Gardner A et al. C-Linker Accounts for Differential Sensitivity of ERG1 and ERG2 K+ Channels to RPR260243-Induced Slow Deactivation.
Mol. Pharmacol., 2015 Jul , 88 (19-28).

95

Issa NP et al. QT interval prolongation in a patient with LQT2 on levetiracetam.
Seizure, 2015 Jul , 29 (134-6).

96

Li L et al. Genetic variants of potassium voltage-gated channel genes (KCNQ1, KCNH2, and KCNE1) affected the risk of atrial fibrillation in elderly patients.
Genet Test Mol Biomarkers, 2015 Jul , 19 (359-65).

97

Wang Y et al. Arsenic trioxide inhibits breast cancer cell growth via microRNA-328/hERG pathway in MCF-7 cells.
Mol Med Rep, 2015 Jul , 12 (1233-8).

98

Wu ZJ et al. Characterization of a Chinese KCNQ1 mutation (R259H) that shortens repolarization and causes short QT syndrome 2.
J Geriatr Cardiol, 2015 Jul , 12 (394-401).

99

Barsanti PA et al. Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors.
ACS Med Chem Lett, 2015 Jan 8 , 6 (42-6).

100

Wiśniowska B et al. Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents.
J Appl Toxicol, 2015 Jan 5 , ().

101

Perez-Neut M et al. Stimulation of hERG1 channel activity promotes a calcium-dependent degradation of cyclin E2, but not cyclin E1, in breast cancer cells.
Oncotarget, 2015 Jan 30 , 6 (1631-9).

102

Vedani A et al. OpenVirtualToxLab--a platform for generating and exchanging in silico toxicity data.
Toxicol. Lett., 2015 Jan 22 , 232 (519-32).

103

Saber S et al. Complex genetic background in a large family with Brugada syndrome.
Physiol Rep, 2015 Jan 1 , 3 ().

104

Lynch SM et al. N-Aryl azacycles as novel sodium channel blockers.
Bioorg. Med. Chem. Lett., 2015 Jan 1 , 25 (48-52).

105

Riuró H et al. Genetic analysis, in silico prediction, and family segregation in long QT syndrome.
Eur. J. Hum. Genet., 2015 Jan , 23 (79-85).

106

Xiang F et al. Plectasin, first animal toxin-like fungal defensin blocking potassium channels through recognizing channel pore region.
Toxins (Basel), 2015 Jan , 7 (34-42).

107

Orvos P et al. Effects of Chelidonium majus extracts and major alkaloids on hERG potassium channels and on dog cardiac action potential - a safety approach.
Fitoterapia, 2015 Jan , 100 (156-65).

108

Martin NJ et al. Indole alkaloids from the Marquesan plant Rauvolfia nukuhivensis and their effects on ion channels.
Phytochemistry, 2015 Jan , 109 (84-95).

109

Kubo T et al. Phosphatidylinositol4-phosphate 5-kinase prevents the decrease in the HERG potassium current induced by Gq protein-coupled receptor stimulation.
J. Pharmacol. Sci., 2015 Jan , 127 (127-34).

110

Chae YJ et al. Effects of donepezil on hERG potassium channels.
Brain Res., 2015 Feb 9 , 1597 (77-85).

111

Wright PD et al. A High-Throughput Electrophysiology Assay Identifies Inhibitors of the Inwardly Rectifying Potassium Channel Kir7.1.
J Biomol Screen, 2015 Feb 5 , ().

112

Ellis JM et al. Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.
J. Med. Chem., 2015 Feb 26 , 58 (1929-39).

113

Männikkö R et al. Pharmacological and electrophysiological characterisation of hERG activator AZSMO-23.
Br. J. Pharmacol., 2015 Feb 12 , ().

114

Cheng Y et al. An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular Liabilities.
ACS Med Chem Lett, 2015 Feb 12 , 6 (210-5).

115

Gao Z et al. Design and synthesis of a novel series of histamine H3 receptor antagonists through a scaffold hopping strategy.
Bioorg. Med. Chem., 2015 Feb 1 , 23 (429-38).

116

Vijayvergiya V et al. Single channel and ensemble hERG conductance measured in droplet bilayers.
Biomed Microdevices, 2015 Feb , 17 (12).

117

Zhang H et al. Reporting sodium channel activity using calcium flux: pharmacological promiscuity of cardiac Nav1.5.
Mol. Pharmacol., 2015 Feb , 87 (207-17).

118

de Llano CT et al. Further evidence of the association between LQT syndrome and epilepsy in a family with KCNQ1 pathogenic variant.
Seizure, 2015 Feb , 25 (65-7).

119

Pulici M et al. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
ChemMedChem, 2015 Feb , 10 (276-95).

120

Gasparoli L et al. New pyrimido-indole compound CD-160130 preferentially inhibits the KV11.1B isoform and produces antileukemic effects without cardiotoxicity.
Mol. Pharmacol., 2015 Feb , 87 (183-96).

121

Oliván-Viguera A et al. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.
Mol. Pharmacol., 2015 Feb , 87 (338-48).

122

Wu CS et al. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study.
J Am Heart Assoc, 2015 Feb , 4 ().

123

Yu Z et al. Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors.
Br. J. Pharmacol., 2015 Feb , 172 (940-55).

124

Zhu W et al. Molecular motions that shape the cardiac action potential: Insights from voltage clamp fluorometry.
Prog. Biophys. Mol. Biol., 2015 Dec 25 , ().

125

Obergrussberger A et al. Automated Patch Clamp Meets High-Throughput Screening: 384 Cells Recorded in Parallel on a Planar Patch Clamp Module.
J Lab Autom, 2015 Dec 23 , ().

126

Li X et al. Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.
Arch. Toxicol., 2015 Dec 16 , ().

127

Sviripa VM et al. Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin.
Org. Biomol. Chem., 2015 Dec 15 , 14 (74-84).

128

Sundby E et al. In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Eur J Pharm Sci, 2015 Dec 1 , 80 (56-65).

129

Robyns T et al. Targeted capture sequencing in a large LQTS family reveals a new pathogenic mutation c.2038delG in KCNH2 initially missed due to allelic dropout.
Acta Cardiol, 2015 Dec , 70 (747-9).

130

Kanters JK et al. Combined gating and trafficking defect in Kv11.1 manifests as a malignant long QT syndrome phenotype in a large Danish p.F29L founder family.
Scand. J. Clin. Lab. Invest., 2015 Dec , 75 (699-709).

131

Liang D et al. [Expression of human ether-a-go-go-related gene in laryngeal carcinoma].
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2015 Dec , 29 (2160-3).

132

Zhi D et al. The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides.
Eur J Pharm Sci, 2015 Aug 30 , 76 (149-55).

133

Yang T et al. Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies.
J. Med. Chem., 2015 Aug 27 , 58 (6389-409).

134

Chen J et al. Rab11-dependent Recycling of the Human Ether-a-go-go-related Gene (hERG) Channel.
J. Biol. Chem., 2015 Aug 21 , 290 (21101-13).

135

Oost T et al. Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908.
Bioorg. Med. Chem. Lett., 2015 Aug 15 , 25 (3275-80).

136

Roth GJ et al. Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.
Bioorg. Med. Chem. Lett., 2015 Aug 15 , 25 (3270-4).

137

Yu Z et al. Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers.
J. Med. Chem., 2015 Aug 13 , 58 (5916-29).

138

Anneken L et al. Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking.
Eur. Heart J., 2015 Aug 12 , ().

139

Johannesen L et al. Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Clin. Pharmacol. Ther., 2015 Aug 11 , ().

140

Marostica E et al. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
J Pharmacokinet Pharmacodyn, 2015 Aug 11 , ().

141

Deng Q et al. Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.
Bioorg. Med. Chem. Lett., 2015 Aug 1 , 25 (2958-62).

142

Osterbur ML et al. An Interdomain KCNH2 Mutation Produces an Intermediate Long QT Syndrome.
Hum. Mutat., 2015 Aug , 36 (764-73).

143

Lees-Miller JP et al. Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4.
J. Mol. Cell. Cardiol., 2015 Aug , 85 (71-8).

144

Yasuda C et al. The human ether-a-go-go-related gene (hERG) current inhibition selectively prolongs action potential of midmyocardial cells to augment transmural dispersion.
J. Physiol. Pharmacol., 2015 Aug , 66 (599-607).

145

Zhang C et al. Identification of Low-Risk Adult Congenital LQTS Patients.
J. Cardiovasc. Electrophysiol., 2015 Aug , 26 (853-8).

146

Koponen M et al. Follow-up of 316 molecularly defined pediatric long-QT syndrome patients: clinical course, treatments, and side effects.
Circ Arrhythm Electrophysiol, 2015 Aug , 8 (815-23).

147

de la Peña P et al. Interactions between the N-terminal tail and the gating machinery of hERG K⁺ channels both in closed and open/inactive states.
Pflugers Arch., 2015 Aug , 467 (1747-56).

148

Zhang J et al. [Effects of allitridum on rapidly delayed rectifier potassium current in HEK293 cell line].
Nan Fang Yi Ke Da Xue Xue Bao, 2015 Aug , 35 (1128-32, 1142).

149

Brodney MA et al. Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.
J. Med. Chem., 2015 Apr 9 , 58 (3223-52).

150

Chae YJ et al. Endoxifen, the active metabolite of tamoxifen, inhibits cloned hERG potassium channels.
Eur. J. Pharmacol., 2015 Apr 5 , 752 (1-7).

151

Williams VS et al. Multiplex ligation-dependent probe amplification copy number variant analysis in patients with acquired long QT syndrome.
Europace, 2015 Apr , 17 (635-41).

152

Erdem M et al. herg1b expression as a potential specific marker in pediatric acute myeloid leukemia patients with HERG 897K/K genotype.
Pediatr Hematol Oncol, 2015 Apr , 32 (182-92).

153

Ferreiro SF et al. Acute cardiotoxicity evaluation of the marine biotoxins OA, DTX-1 and YTX.
Toxins (Basel), 2015 Apr , 7 (1030-47).

154

Melgari D et al. hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.
J Am Heart Assoc, 2015 Apr , 4 ().

155

Wang J et al. MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel.
J. Mol. Neurosci., 2015 Apr , 55 (985-94).

156

Teng G et al. Role of mutation and pharmacologic block of human KCNH2 in vasculogenesis and fetal mortality: partial rescue by transforming growth factor-β.
Circ Arrhythm Electrophysiol, 2015 Apr , 8 (420-8).

157

Han SN et al. The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.
Acta Pharmacol. Sin., 2015 Apr , 36 (454-62).

158

Obejero-Paz CA et al. Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk.
Sci Rep, 2015 , 5 (17623).

159

Badyra B et al. How in vitro influences in silico utilized for the prediction of in vivo - pilot study of the drug-induced pro-arrhythmic potency prediction.
Folia Med Cracov, 2015 , 55 (5-19).

160

Jouni M et al. Toward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome.
J Am Heart Assoc, 2015 , 4 ().

161

Chang YS et al. Mutation Analysis of KCNQ1, KCNH2 and SCN5A Genes in Taiwanese Long QT Syndrome Patients.
Int Heart J, 2015 , 56 (450-3).

162

Leong IU et al. Assessment of the predictive accuracy of five in silico prediction tools, alone or in combination, and two metaservers to classify long QT syndrome gene mutations.
BMC Med. Genet., 2015 , 16 (34).

163

Stephens RF et al. Selectivity filters and cysteine-rich extracellular loops in voltage-gated sodium, calcium, and NALCN channels.
Front Physiol, 2015 , 6 (153).

164

Steffensen AB et al. High incidence of functional ion-channel abnormalities in a consecutive Long QT cohort with novel missense genetic variants of unknown significance.
Sci Rep, 2015 , 5 (10009).

165

Stimers JR et al. Overexpression of the Large-Conductance, Ca2+-Activated K+ (BK) Channel Shortens Action Potential Duration in HL-1 Cardiomyocytes.
PLoS ONE, 2015 , 10 (e0130588).

166

Pugsley MK et al. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Handb Exp Pharmacol, 2015 , 229 (149-203).

167

Hisajima N et al. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Biol. Pharm. Bull., 2015 , 38 (781-4).

168

Martelli A et al. Inhibitors of the renal outer medullary potassium channel: a patent review.
Expert Opin Ther Pat, 2015 , 25 (1035-51).

169

Shi YQ et al. Mechanisms underlying probucol-induced hERG-channel deficiency.
Drug Des Devel Ther, 2015 , 9 (3695-704).

170

Molbaek K et al. High yield purification of full-length functional hERG K+ channels produced in Saccharomyces cerevisiae.
Microb. Cell Fact., 2015 , 14 (15).

171

Okada M et al. Increase in the titer of lentiviral vectors expressing potassium channels by current blockade during viral vector production.
BMC Neurosci, 2015 , 16 (30).

172

Allegue C et al. Genetic Analysis of Arrhythmogenic Diseases in the Era of NGS: The Complexity of Clinical Decision-Making in Brugada Syndrome.
PLoS ONE, 2015 , 10 (e0133037).

173

Shi YQ et al. High Glucose Represses hERG K+ Channel Expression through Trafficking Inhibition.
Cell. Physiol. Biochem., 2015 , 37 (284-96).

174

Lastraioli E et al. hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers.
Biomed Res Int, 2015 , 2015 (896432).

175

Giacomini E et al. A ligand-based virtual screening approach to identify small molecules as HERG channel activators.
Comb. Chem. High Throughput Screen., 2015 , 18 (269-80).

176

Pedersen PJ et al. Molecular Cloning and Functional Expression of the Equine K+ Channel KV11.1 (Ether à Go-Go-Related/KCNH2 Gene) and the Regulatory Subunit KCNE2 from Equine Myocardium.
PLoS ONE, 2015 , 10 (e0138320).

177

Ji N et al. Effect of celastrol on growth inhibition of prostate cancer cells through the regulation of hERG channel in vitro.
Biomed Res Int, 2015 , 2015 (308475).

178

Dey D et al. Acute and chronic toxicity, cytochrome p450 enzyme inhibition, and HERG channel blockade studies with a polyherbal, ayurvedic formulation for inflammation.
Biomed Res Int, 2015 , 2015 (971982).

179

Jing Y et al. In silico prediction of hERG inhibition.
Future Med Chem, 2015 , 7 (571-86).

180

Liu QN et al. Eag Domains Regulate LQT Mutant hERG Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
PLoS ONE, 2015 , 10 (e0123951).

181

Du F et al. Global analysis reveals families of chemical motifs enriched for HERG inhibitors.
PLoS ONE, 2015 , 10 (e0118324).

182

Vonderlin N et al. Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related gene channels: mode of action.
Drug Des Devel Ther, 2015 , 9 (867-77).

183

Wu W et al. Concatenated hERG1 tetramers reveal stoichiometry of altered channel gating by RPR-260243.
Mol. Pharmacol., 2015 , 87 (401-9).

184

Vicente J et al. Comprehensive T wave Morphology Assessment in a Randomized Clinical Study of Dofetilide, Quinidine, Ranolazine, and Verapamil.
J Am Heart Assoc, 2015 , 4 ().

185

Rast G et al. Solubility assessment and on-line exposure confirmation in a patch-clamp assay for hERG (human ether-a-go-go-related gene) potassium channel inhibition.
J Pharmacol Toxicol Methods, 2014 Sep-Oct , 70 (182-7).

186

Gibson JK et al. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents.
J Pharmacol Toxicol Methods, 2014 Nov-Dec , 70 (255-67).

187

Mirams GR et al. Prediction of Thorough QT study results using action potential simulations based on ion channel screens.
J Pharmacol Toxicol Methods, 2014 Nov-Dec , 70 (246-54).

188

Rodríguez-Menchaca AA et al. Impact of the whole-cell patch-clamp configuration on the pharmacological assessment of the hERG channel: trazodone as a case example.
J Pharmacol Toxicol Methods, 2014 May-Jun , 69 (237-44).

189

Kim TW et al. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
J Pharmacol Toxicol Methods, 2014 Jan-Feb , 69 (49-60).

190

Cai Y et al. Down-regulation of ether-a-go-go-related gene potassium channel protein through sustained stimulation of AT1 receptor by angiotensin II.
Biochem. Biophys. Res. Commun., 2014 Sep 26 , 452 (852-7).

191

Washburn WN et al. Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate.
J. Med. Chem., 2014 Sep 25 , 57 (7509-22).

192

Brudeli B et al. Discovery and pharmacological profile of new hydrophilic 5-HT(4) receptor antagonists.
Bioorg. Med. Chem. Lett., 2014 Sep 15 , 24 (4598-602).

193

Ng CA et al. Multiple interactions between cytoplasmic domains regulate slow deactivation of Kv11.1 channels.
J. Biol. Chem., 2014 Sep 12 , 289 (25822-32).

194

Shopp GM et al. Liposomes ameliorate Crizotinib- and Nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation.
Anticancer Res., 2014 Sep , 34 (4733-40).

195

Han SN et al. Identification and functional characterization of the human ether-a-go-go-related gene Q738X mutant associated with hereditary long QT syndrome type 2.
Int. J. Mol. Med., 2014 Sep , 34 (810-5).

196

Choi SH et al. Ginseng gintonin activates the human cardiac delayed rectifier K+ channel: involvement of Ca2+/calmodulin binding sites.
Mol. Cells, 2014 Sep , 37 (656-63).

197

Bartok A et al. Margatoxin is a non-selective inhibitor of human Kv1.3 K(+) channels.
Toxicon, 2014 Sep , 87 (6-16).

198

Kim Y et al. Novel thienopyrimidinones as mGluR1 antagonists.
Eur J Med Chem, 2014 Oct 6 , 85 (629-37).

199

Kauthale RR et al. Assessment of temperature-induced hERG channel blockade variation by drugs.
J Appl Toxicol, 2014 Oct 28 , ().

200

Kratz JM et al. Experimentally validated HERG pharmacophore models as cardiotoxicity prediction tools.
J Chem Inf Model, 2014 Oct 27 , 54 (2887-901).

201

Comer E et al. Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agents.
J. Med. Chem., 2014 Oct 23 , 57 (8496-502).

202

Perlmutter JI et al. Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
J. Med. Chem., 2014 Oct 23 , 57 (8540-62).

203

Patanè S HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs.
Int. J. Cardiol., 2014 Oct 20 , 176 (1082-5).

204

Nogawa H et al. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
Eur. J. Pharmacol., 2014 Oct 15 , 741 (336-9).

205

Olde Nordkamp LR et al. Syncope in genotype-negative long QT syndrome family members.
Am. J. Cardiol., 2014 Oct 15 , 114 (1223-8).

206

Wu W et al. Cooperative subunit interactions mediate fast C-type inactivation of hERG1 K+ channels.
J. Physiol. (Lond.), 2014 Oct 15 , 592 (4465-80).

207

Reck F et al. Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.
Bioorg. Med. Chem., 2014 Oct 1 , 22 (5392-409).

208

Hull CM et al. Regional flexibility in the S4-S5 linker regulates hERG channel closed-state stabilization.
Pflugers Arch., 2014 Oct , 466 (1911-9).

209

Terentyev D et al. Hyperphosphorylation of RyRs underlies triggered activity in transgenic rabbit model of LQT2 syndrome.
Circ. Res., 2014 Nov 7 , 115 (919-28).

210

Anwar-Mohamed A et al. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity.
Toxicol. Lett., 2014 Nov 4 , 230 (382-92).

211

Linder T et al. Structural insights into trapping and dissociation of small molecules in K⁺ channels.
J Chem Inf Model, 2014 Nov 24 , 54 (3218-28).

212

Colenso CK et al. Voltage sensor gating charge transfer in a hERG potassium channel model.
Biophys. J., 2014 Nov 18 , 107 (L25-8).

213

Balasuriya D et al. A direct interaction between the sigma-1 receptor and the hERG voltage-gated K+ channel revealed by atomic force microscopy and homogeneous time-resolved fluorescence (HTRF®).
J. Biol. Chem., 2014 Nov 14 , 289 (32353-63).

214

Scott JS et al. Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.
J. Med. Chem., 2014 Nov 13 , 57 (8984-98).

215

Le Manach C et al. Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a softfocus kinase library: part 2.
J. Med. Chem., 2014 Nov 13 , 57 (8839-48).

216

Jensen JE et al. Understanding the molecular basis of toxin promiscuity: the analgesic sea anemone peptide APETx2 interacts with acid-sensing ion channel 3 and hERG channels via overlapping pharmacophores.
J. Med. Chem., 2014 Nov 13 , 57 (9195-203).

217

Nikolov NG et al. hERG blocking potential of acids and zwitterions characterized by three thresholds for acidity, size and reactivity.
Bioorg. Med. Chem., 2014 Nov 1 , 22 (6004-13).

218

Luo F et al. Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel.
Mol Biosyst, 2014 Nov , 10 (2863-9).

219

Gong Q et al. Upregulation of functional Kv11.1 isoform expression by inhibition of intronic polyadenylation with antisense morpholino oligonucleotides.
J. Mol. Cell. Cardiol., 2014 Nov , 76 (26-32).

220

Loewe A et al. In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology.
Europace, 2014 Nov , 16 Suppl 4 (iv30-iv38).

221

Zhao X et al. The rescuable function and mechanism of resveratrol on As₂O₃-induced hERG K⁺ channel deficiency.
Naunyn Schmiedebergs Arch. Pharmacol., 2014 Nov , 387 (1079-89).

222

Johannesen L et al. Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil.
Clin. Pharmacol. Ther., 2014 Nov , 96 (549-58).

223

Frolov RV et al. Celecoxib and ion channels: a story of unexpected discoveries.
Eur. J. Pharmacol., 2014 May 5 , 730 (61-71).

224

Shi S et al. Chronic N-Methyl-d-Aspartate Receptor Activation Induces Cardiac Electrical Remodeling and Increases Susceptibility to Ventricular Arrhythmias.
Pacing Clin Electrophysiol, 2014 May 30 , ().

225

Ke Y et al. Role of the cytoplasmic N-terminal Cap and Per-Arnt-Sim (PAS) domain in trafficking and stabilization of Kv11.1 channels.
J. Biol. Chem., 2014 May 16 , 289 (13782-91).

226

Pier DM et al. Long-term Channel Block is Required to Inhibit Cellular Transformation by Human Ether-a-go-go-related Gene (Herg1) Potassium Channels.
Mol. Pharmacol., 2014 May 15 , ().

227

Wang S et al. β1-adrenergic regulation of rapid component of delayed rectifier K+ currents in guinea-pig cardiac myocytes.
Mol Med Rep, 2014 May , 9 (1923-8).

228

Wang Q et al. Gain-of-function KCNH2 mutations in patients with Brugada syndrome.
J. Cardiovasc. Electrophysiol., 2014 May , 25 (522-30).

229

Hill AP et al. Kinetics of drug interaction with the Kv11.1 potassium channel.
Mol. Pharmacol., 2014 May , 85 (769-76).

230

Lee JH et al. Synthesis and biological evaluation of 1-(isoxazol-5-ylmethylaminoethyl)-4-phenyl tetrahydropyridine and piperidine derivatives as potent T-type calcium channel blockers with antinociceptive effect in a neuropathic pain model.
Eur J Med Chem, 2014 Mar 3 , 74 (246-57).

231

Crociani O et al. hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implications.
Clin. Cancer Res., 2014 Mar 15 , 20 (1502-12).

232

Schumacher-Bass SM et al. Role for myosin-V motor proteins in the selective delivery of Kv channel isoforms to the membrane surface of cardiac myocytes.
Circ. Res., 2014 Mar 14 , 114 (982-92).

233

Bhuiyan ZA et al. Not all pathogenic mutations are pathogenic: KCNH2 mutations in two sisters with tetralogy of Fallot.
Int. J. Cardiol., 2014 Mar 1 , 172 (276-7).

234

Koenig X et al. Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk.
Addict Biol, 2014 Mar , 19 (237-9).

235

Rodríguez-Ravelo R et al. A K⁺ channel blocking peptide from the Cuban scorpion Rhopalurus garridoi.
Peptides, 2014 Mar , 53 (42-7).

236

Yu H et al. Comparison of read-through effects of aminoglycosides and PTC124 on rescuing nonsense mutations of HERG gene associated with long QT syndrome.
Int. J. Mol. Med., 2014 Mar , 33 (729-35).

237

Yang Y et al. [Construction of pcDNA3-HERG-G572R expression vector and establishment of a cell line stably expressing HKE-HERG-G572R].
Nan Fang Yi Ke Da Xue Xue Bao, 2014 Mar , 34 (308-11).

238

Young JC The role of the cytosolic HSP70 chaperone system in diseases caused by misfolding and aberrant trafficking of ion channels.
Dis Model Mech, 2014 Mar , 7 (319-29).

239

Pond AL et al. The mERG1a channel modulates skeletal muscle MuRF1, but not MAFbx, expression.
Muscle Nerve, 2014 Mar , 49 (378-88).

240

Loewe A et al. Arrhythmic potency of human ether-a-go-go-related gene mutations L532P and N588K in a computational model of human atrial myocytes.
Europace, 2014 Mar , 16 (435-43).

241

Baumgartner S et al. Electrophysiological and Morphological Maturation of Murine Fetal Cardiomyocytes During Electrical Stimulation In Vitro.
J. Cardiovasc. Pharmacol. Ther., 2014 Jun 9 , ().

242

Priest JR et al. Molecular Diagnosis of Long-QT syndrome at 10 Days of Life by Rapid Whole Genome Sequencing.
Heart Rhythm, 2014 Jun 25 , ().

243

Coleman N et al. New Positive KCa Channel Gating Modulators with Selectivity for KCa3.1.
Mol. Pharmacol., 2014 Jun 23 , ().

244

Sviripa VM et al. 2',6'-Dihalostyrylanilines, Pyridines and Pyrimidines for the Inhibition of the Catalytic Subunit of Methionine S-Adenosyltransferase-2 (MAT2A).
J. Med. Chem., 2014 Jun 20 , ().

245

Hameed P S et al. Novel N-Linked Aminopiperidine-Based Gyrase Inhibitors with Improved hERG and in Vivo Efficacy against Mycobacterium tuberculosis.
J. Med. Chem., 2014 Jun 12 , 57 (4889-905).

246

Li Q et al. Insight into the molecular interaction between the cyclic nucleotide-binding homology domain and the eag domain of the hERG channel.
FEBS Lett., 2014 Jun 12 , ().

247

Mehta A et al. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.
Cardiovasc. Res., 2014 Jun 1 , 102 (497-506).

248

Wang T et al. Muscarinic receptor activation increases hERG channel expression through phosphorylation of ubiquitin ligase Nedd4-2.
Mol. Pharmacol., 2014 Jun , 85 (877-86).

249

Moorthy NS et al. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools.
J Enzyme Inhib Med Chem, 2014 Jun , 29 (317-24).

250

Pillozzi S et al. Differential expression of hERG1A and hERG1B genes in pediatric acute lymphoblastic leukemia identifies different prognostic subgroups.
Leukemia, 2014 Jun , 28 (1352-5).

251

Feng J et al. HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96.
Oncotarget, 2014 Jul 30 , 5 (5832-44).

252

Sherhod R et al. Emerging pattern mining to aid toxicological knowledge discovery.
J Chem Inf Model, 2014 Jul 28 , 54 (1864-79).

253

Romero L et al. In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
J. Mol. Cell. Cardiol., 2014 Jul , 72 (126-37).

254

Bando S et al. Congenital long QT syndrome with compound mutations in the KCNH2 gene.
Heart Vessels, 2014 Jul , 29 (554-9).

255

Glengarry JM et al. Long QT molecular autopsy in sudden infant death syndrome.
Arch. Dis. Child., 2014 Jul , 99 (635-40).

256

Luna-Ramírez K et al. Structure, molecular modeling, and function of the novel potassium channel blocker urotoxin isolated from the venom of the Australian scorpion Urodacus yaschenkoi.
Mol. Pharmacol., 2014 Jul , 86 (28-41).

257

González Cabrera D et al. 2,4-Diaminothienopyrimidines as Orally Active Antimalarial Agents.
J. Med. Chem., 2014 Jan 28 , ().

258

Radresa O et al. Roles of PKC Isoforms in PMA-Induced Modulation of the hERG Channel (Kv11.1).
J Biomol Screen, 2014 Jan 24 , ().

259

Gohlke BO et al. SuperPain--a resource on pain-relieving compounds targeting ion channels.
Nucleic Acids Res., 2014 Jan 1 , 42 (D1107-12).

260

Yu Z et al. Allosteric modulators of the hERG K(+) channel: Radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
Toxicol. Appl. Pharmacol., 2014 Jan 1 , 274 (78-86).

261

Du D et al. In-silico modeling of glycosylation modulation dynamics in HERG ion channels and cardiac electrical signals.
IEEE J Biomed Health Inform, 2014 Jan , 18 (205-14).

262

Chen A et al. Integrated platform for functional monitoring of biomimetic heart sheets derived from human pluripotent stem cells.
Biomaterials, 2014 Jan , 35 (675-83).

263

Hata Y et al. Identification and characterization of a novel genetic mutation with prolonged QT syndrome in an unexplained postoperative death.
Int. J. Legal Med., 2014 Jan , 128 (105-15).

264

Schulze V et al. The opioid methadone induces a local anaesthetic-like inhibition of the cardiac Na⁺ channel, Na(v)1.5.
Br. J. Pharmacol., 2014 Jan , 171 (427-37).

265

Mints Y et al. Single nucleotide polymorphisms in proximity to K-channel genes are associated with decreased longitudinal QTc variance.
Ann Noninvasive Electrocardiol, 2014 Jan , 19 (63-9).

266

Dempsey CE et al. Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block.
J Chem Inf Model, 2014 Feb 24 , 54 (601-12).

267

Nair AG et al. IV. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: improved PK, hERG and metabolic profiles.
Bioorg. Med. Chem. Lett., 2014 Feb 15 , 24 (1085-8).

268

Choi YJ et al. Successful reduction of off-target hERG toxicity by structural modification of a T-type calcium channel blocker.
Bioorg. Med. Chem. Lett., 2014 Feb 1 , 24 (880-3).

269

Shin DS et al. A novel assessment of nefazodone-induced hERG inhibition by electrophysiological and stereochemical method.
Toxicol. Appl. Pharmacol., 2014 Feb 1 , 274 (361-71).

270

Thurner P et al. Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.
J. Pharmacol. Exp. Ther., 2014 Feb , 348 (346-58).

271

Ma Q et al. Screening for cardiac HERG potassium channel interacting proteins using the yeast two-hybrid technique.
Cell Biol. Int., 2014 Feb , 38 (239-45).

272

Ferreiro SF et al. In vivo arrhythmogenicity of the marine biotoxin azaspiracid-2 in rats.
Arch. Toxicol., 2014 Feb , 88 (425-34).

273

Zhang Y et al. The SCN5A mutation A1180V is associated with electrocardiographic features of LQT3.
Pediatr Cardiol, 2014 Feb , 35 (295-300).

274

Roder K et al. RING finger protein RNF207, a novel regulator of cardiac excitation.
J. Biol. Chem., 2014 Dec 5 , 289 (33730-40).

275

Jones DK et al. hERG 1b is critical for human cardiac repolarization.
Proc. Natl. Acad. Sci. U.S.A., 2014 Dec 16 , 111 (18073-7).

276

Ogiyama T et al. Discovery of novel tetrahydroisoquinoline derivatives as orally active N-type calcium channel blockers with high selectivity for hERG potassium channels.
Bioorg. Med. Chem., 2014 Dec 15 , 22 (6899-907).

277

Lim CJ et al. Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists.
Bioorg. Med. Chem. Lett., 2014 Dec 15 , 24 (5832-5).

278

Harcken C et al. Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.
ACS Med Chem Lett, 2014 Dec 11 , 5 (1318-23).

279

Epstein O et al. Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
J. Med. Chem., 2014 Dec 11 , 57 (9796-810).

280

Dineen TA et al. Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718).
J. Med. Chem., 2014 Dec 11 , 57 (9811-31).

281

Strauss KA et al. A population-based study of KCNH7 p.Arg394His and bipolar spectrum disorder.
Hum. Mol. Genet., 2014 Dec 1 , 23 (6395-406).

282

Bond R et al. Congenital long QT syndrome: a case report of LQT2 and LQT13 in a neonate.
Europace, 2014 Dec , 16 (1807).

283

Ferreiro SF et al. In vitro chronic effects on hERG channel caused by the marine biotoxin azaspiracid-2.
Toxicon, 2014 Dec , 91 (69-75).

284

Lin EC et al. Mouse ERG K(+) channel clones reveal differences in protein trafficking and function.
J Am Heart Assoc, 2014 Dec , 3 (e001491).

285

Zhang KP et al. Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects.
Acta Pharmacol. Sin., 2014 Dec , 35 (1473-84).

286

Li Q et al. Structural insight into the transmembrane segments 3 and 4 of the hERG potassium channel.
J. Pept. Sci., 2014 Dec , 20 (935-44).

287

Li P et al. The human ether-a-go-go-related gene activator NS1643 enhances epilepsy-associated KCNQ channels.
J. Pharmacol. Exp. Ther., 2014 Dec , 351 (596-604).

288

Wang Y et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing.
J. Am. Coll. Cardiol., 2014 Aug 5 , 64 (451-9).

289

Schmidtke P et al. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
J Chem Inf Model, 2014 Aug 25 , 54 (2320-33).

290

Thomson SJ et al. Concerted all-or-none subunit interactions mediate slow deactivation of human ether-à-go-go-related gene K+ channels.
J. Biol. Chem., 2014 Aug 22 , 289 (23428-36).

291

Long Y et al. Inhibition of HERG potassium channels by domiphen bromide and didecyl dimethylammonium bromide.
Eur. J. Pharmacol., 2014 Aug 15 , 737 (202-9).

292

Cid JM et al. Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor.
J. Med. Chem., 2014 Aug 14 , 57 (6495-512).

293

Spencer CI et al. Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia.
Stem Cell Reports, 2014 Aug 12 , 3 (269-81).

294

Hajj A et al. KCNH2 polymorphism and methadone dosage interact to enhance QT duration.
Drug Alcohol Depend, 2014 Aug 1 , 141 (34-8).

295

Yun J et al. Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
Bioorg. Med. Chem. Lett., 2014 Aug 1 , 24 (3234-7).

296

Imai M et al. Novel KCNQ1 splicing mutation in patients with forme fruste LQT1 aggravated by hypokalemia.
J Cardiol, 2014 Aug , 64 (121-6).

297

Liu LL et al. Novel Bayesian classification models for predicting compounds blocking hERG potassium channels.
Acta Pharmacol. Sin., 2014 Aug , 35 (1093-102).

298

Alexandrou AJ et al. The human ether-a'-go-go related gene (hERG) K+ channel blockade by the investigative selective-serotonin reuptake inhibitor CONA-437: limited dependence on S6 aromatic residues.
J. Physiol. Pharmacol., 2014 Aug , 65 (511-23).

299

Gong Q et al. Identification of Kv11.1 isoform switch as a novel pathogenic mechanism of long-QT syndrome.
Circ Cardiovasc Genet, 2014 Aug , 7 (482-90).

300

Gong Q et al. Position of premature termination codons determines susceptibility of hERG mutations to nonsense-mediated mRNA decay in long QT syndrome.
Gene, 2014 Apr 15 , 539 (190-7).

301

Weeke P et al. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome.
J. Am. Coll. Cardiol., 2014 Apr 15 , 63 (1430-7).

302

Martinson AS et al. Functional evolution of Erg potassium channel gating reveals an ancient origin for IKr.
Proc. Natl. Acad. Sci. U.S.A., 2014 Apr 15 , 111 (5712-7).

303

Chanséaume A et al. [KCNH2 gene new mutation in a patient with prior diagnosis of epilepsy].
Rev. Neurol. (Paris), 2014 Apr , 170 (304-5).

304

Heijman J et al. Cardiac safety assays.
Curr Opin Pharmacol, 2014 Apr , 15 (16-21).

305

Noriega-Navarro R et al. Novel TASK channels inhibitors derived from dihydropyrrolo[2,1-a]isoquinoline.
Neuropharmacology, 2014 Apr , 79 (28-36).

306

Silvestre JS et al. Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics.
J. Psychopharmacol. (Oxford), 2014 Apr , 28 (329-40).

307

Sanguinetti MC HERG1 channel agonists and cardiac arrhythmia.
Curr Opin Pharmacol, 2014 Apr , 15 (22-7).

308

Wu W et al. Stoichiometry of altered hERG1 channel gating by small molecule activators.
J. Gen. Physiol., 2014 Apr , 143 (499-512).

309

Wang D et al. Cardiac channelopathy testing in 274 ethnically diverse sudden unexplained deaths.
Forensic Sci. Int., 2014 Apr , 237 (90-9).

310

Tester DJ et al. GENETICS OF LONG QT SYNDROME.
Methodist Debakey Cardiovasc J, 2014 1 , 10 (29-33).

311

Zhang P et al. New Aspects of HERG K(+) Channel Function Depending upon Cardiac Spatial Heterogeneity.
PLoS ONE, 2014 , 9 (e72181).

312

Iyer V et al. Modeling Tissue- and Mutation- Specific Electrophysiological Effects in the Long QT Syndrome: Role of the Purkinje Fiber.
PLoS ONE, 2014 , 9 (e97720).

313

Sivagangabalan G et al. Regional ion channel gene expression heterogeneity and ventricular fibrillation dynamics in human hearts.
PLoS ONE, 2014 , 9 (e82179).

314

Shao XD et al. The mechanism of COX-2 regulating HERG channel in gastric cancer cells.
Bratisl Lek Listy, 2014 , 115 (487-91).

315

Zheng X et al. Natural antisense transcripts regulate the neuronal stress response and excitability.
Elife, 2014 , 3 (e01849).

316

Christiansen M et al. Mutations in Danish patients with long QT syndrome and the identification of a large founder family with p.F29L in KCNH2.
BMC Med. Genet., 2014 , 15 (31).

317

Durdagi S et al. Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.
BMC Pharmacol Toxicol, 2014 , 15 (14).

318

Schlichter LC et al. Regulation of hERG and hEAG channels by Src and by SHP-1 tyrosine phosphatase via an ITIM region in the cyclic nucleotide binding domain.
PLoS ONE, 2014 , 9 (e90024).

319

Munoz C et al. Up-regulation of Kir2.1 (KCNJ2) by the serum & glucocorticoid inducible SGK3.
Cell. Physiol. Biochem., 2014 , 33 (491-500).

320

Rizzo A et al. Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities.
J. Exp. Clin. Cancer Res., 2014 , 33 (81).

321

Shimizu W Clinical and genetic diagnosis for inherited cardiac arrhythmias.
J Nippon Med Sch, 2014 , 81 (203-10).

322

Aslanidis A et al. RETINA-specific expression of Kcnv2 is controlled by cone-rod homeobox (Crx) and neural retina leucine zipper (Nrl).
Adv. Exp. Med. Biol., 2014 , 801 (31-41).

323

Jimmy JJ et al. Clinical characteristics of patients with congenital long QT syndrome and bigenic mutations.
Chin. Med. J., 2014 , 127 (1482-6).

324

Polonchuk L Industrializing electrophysiology: HT automated patch clamp on SyncroPatch® 96 using instant frozen cells.
Methods Mol. Biol., 2014 , 1183 (81-92).

325

Danker T et al. Early identification of hERG liability in drug discovery programs by automated patch clamp.
Front Pharmacol, 2014 , 5 (203).

326

Braga RC et al. Tuning HERG out: antitarget QSAR models for drug development.
Curr Top Med Chem, 2014 , 14 (1399-415).

327

Staudacher I et al. HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells.
PLoS ONE, 2014 , 9 (e88164).

328

Li G et al. Allitridin reduces I Kr current by disrupting the trafficking of human ether-à-go-go-related gene channels.
Cardiology, 2014 , 128 (1-8).

329

Pakladok T et al. Up-regulation of hERG K⁺ channels by B-RAF.
PLoS ONE, 2014 , 9 (e87457).

330

Yamaguchi Y et al. Glycine/Serine polymorphism at position 38 influences KCNE1 subunit's modulatory actions on rapid and slow delayed rectifier K+ currents.
Circ. J., 2014 , 78 (610-8).

331

Hu YT et al. Open conformation of hERG channel turrets revealed by a specific scorpion toxin BmKKx2.
Cell Biosci, 2014 , 4 (18).

332

Nielsen JB et al. Gain-of-function mutations in potassium channel subunit KCNE2 associated with early-onset lone atrial fibrillation.
Biomark Med, 2014 , 8 (557-70).

333

Goodchild SJ et al. Gating charge movement precedes ionic current activation in hERG channels.
Channels (Austin), 2014 , 8 (84-9).

334

Liu J et al. Patch-clamp technique in ESC-derived cardiomyocytes.
Methods Mol. Biol., 2014 , 1181 (203-14).

335

Guo X et al. Discovery of aroyl piperazine derivatives as IKr & IKs dual inhibitors for cardiac arrhythmia treatment.
Med Chem, 2014 , 10 (497-505).

336

Sanders NG et al. Antimalarial efficacy of hydroxyethylapoquinine (SN-119) and its derivatives.
Antimicrob. Agents Chemother., 2014 , 58 (820-7).

337

Yu CC et al. Apamin does not inhibit human cardiac Na+ current, L-type Ca2+ current or other major K+ currents.
PLoS ONE, 2014 , 9 (e96691).

338

Tanaka H et al. Effect of terfenadine and pentamidine on the HERG channel and its intracellular trafficking: combined analysis with automated voltage clamp and confocal microscopy.
Biol. Pharm. Bull., 2014 , 37 (1826-30).

339

Lin TF et al. The Eag domain regulates the voltage-dependent inactivation of rat Eag1 K+ channels.
PLoS ONE, 2014 , 9 (e110423).

340

Anderson CL et al. Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome.
Nat Commun, 2014 , 5 (5535).

341

Tong WC et al. Computational modeling reveals key contributions of KCNQ and hERG currents to the malleability of uterine action potentials underpinning labor.
PLoS ONE, 2014 , 9 (e114034).

342

Hancox JC et al. Modification of KCNH2-encoded cardiac potassium channels by KCNE1 polymorphism.
Circ. J., 2014 , 78 (2330).

343

Schweigmann U et al. Elevated heart rate triggers action potential alternans and sudden death. translational study of a homozygous KCNH2 mutation.
PLoS ONE, 2014 , 9 (e103150).

344

Zhang K et al. Berberine induces hERG channel deficiency through trafficking inhibition.
Cell. Physiol. Biochem., 2014 , 34 (691-702).

345

Lee SH et al. Blockade of HERG human K+ channels by the antidepressant drug paroxetine.
Biol. Pharm. Bull., 2014 , 37 (1495-504).

346

Tabata T et al. Modification of KCNH2-encoded cardiac potassium channels by KCNE1 polymorphism.
Circ. J., 2014 , 78 (2331).

347

Lu J et al. Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes.
PLoS ONE, 2014 , 9 (e115648).

348

Guo J et al. Structure driven design of novel human ether-a-go-go-related-gene channel (hERG1) activators.
PLoS ONE, 2014 , 9 (e105553).

349

Zeng H et al. Halide Ion Effects on Human Ether-à-go-go Related Gene Potassium Channel Properties.
Assay Drug Dev Technol, 2013 Nov-Dec , 11 (544-50).

350

Beattie KA et al. Evaluation of an in silico cardiac safety assay: Using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (88-96).

351

Morissette P et al. The anesthetized guinea pig: An effective early cardiovascular derisking and lead optimization model.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (137-49).

352

Elkins RC et al. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (112-22).

353

Himmel HM Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: Effects of reference compounds.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (97-111).

354

Rampe D et al. A history of the role of the hERG channel in cardiac risk assessment.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (13-22).

355

Qu Y et al. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (74-81).

356

Chun YS et al. Cholesterol regulates HERG K+ channel activation by increasing phospholipase C β1 expression.
Channels (Austin), 2013 Jul-Aug , 7 (275-87).

357

Gillie DJ et al. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
J Pharmacol Toxicol Methods, 2013 Jan-Feb , 67 (33-44).

358

Haugaa KH et al. Abnormal electroencephalograms in patients with long QT syndrome.
Heart Rhythm, 2013 Sep 27 , ().

359

Czodrowski P hERG me out.
J Chem Inf Model, 2013 Sep 23 , 53 (2240-51).

360

Park MH et al. Effect of azelastine on cardiac repolarization of guinea-pig cardiomyocytes, hERG K⁺ channel, and human L-type and T-type Ca²⁺ channel.
J. Pharmacol. Sci., 2013 Sep 20 , 123 (67-77).

361

Wang N et al. Procaine, a state-dependent blocker, inhibits HERG channels by helix residue Y652 and F656 in the S6 transmembrane domain.
J. Pharmacol. Sci., 2013 Sep 20 , 123 (25-35).

362

Haitin Y et al. The structural mechanism of KCNH-channel regulation by the eag domain.
Nature, 2013 Sep 19 , 501 (444-8).

363

Diamant UB et al. Electrophysiological Phenotype in the LQTS Mutations Y111C and R518X in the KCNQ1 Gene.
J. Appl. Physiol., 2013 Sep 19 , ().

364

Baczkó I et al. Characterization of a novel multi-functional resveratrol derivative for the treatment of atrial fibrillation.
Br. J. Pharmacol., 2013 Sep 18 , ().

365

Di Veroli GY et al. hERG Inhibitors With Similar Potency But Different Binding Kinetics Do Not Pose the Same Proarrhythmic Risk: Implications for Drug Safety Assessment.
J. Cardiovasc. Electrophysiol., 2013 Sep 12 , ().

366

Cordeiro JM et al. Developmental changes in expression and biophysics of ion channels in the canine ventricle.
J. Mol. Cell. Cardiol., 2013 Sep 10 , 64C (79-89).

367

Hedley PL et al. The Role of CAV3 in Long QT Syndrome: Clinical and Functional Assessment of a Caveolin-3/Kv11.1 Double Heterozygote Versus Caveolin-3 Single Heterozygote.
Circ Cardiovasc Genet, 2013 Sep 10 , ().

368

Liu C et al. Postmortem molecular analysis of KCNQ1, KCNH2, KCNE1 and KCNE2 genes in sudden unexplained nocturnal death syndrome in the Chinese Han population.
Forensic Sci. Int., 2013 Sep 10 , 231 (82-7).

369

Washburn DG et al. The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore.
Bioorg. Med. Chem. Lett., 2013 Sep 1 , 23 (4979-84).

370

Park JK et al. Single Nucleotide Deletion Mutation of KCNH2 Gene is Responsible for LQT Syndrome in a 3-Generation Korean Family.
J. Korean Med. Sci., 2013 Sep , 28 (1388-93).

371

Cheng YM et al. Functional interactions of voltage sensor charges with an S2 hydrophobic plug in hERG channels.
J. Gen. Physiol., 2013 Sep , 142 (289-303).

372

Perry MD et al. Hydrophobic interactions between the voltage sensor and pore mediate inactivation in Kv11.1 channels.
J. Gen. Physiol., 2013 Sep , 142 (275-88).

373

Nawathe PA et al. An LQTS6 MiRP1 mutation suppresses pacemaker current and is associated with sinus bradycardia.
J. Cardiovasc. Electrophysiol., 2013 Sep , 24 (1021-7).

374

Zhang P et al. Blockade of the human ether-a-go-go-related gene potassium channel by ketamine.
J. Pharm. Pharmacol., 2013 Sep , 65 (1321-8).

375

Fischer F et al. Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels.
Naunyn Schmiedebergs Arch. Pharmacol., 2013 Sep , 386 (795-804).

376

Olesen MS et al. Very early onset lone atrial fibrillation patients have a high prevalence of rare variants in genes previously associated with atrial fibrillation.
Heart Rhythm, 2013 Oct 18 , ().

377

Niculescu D et al. Erg potassium currents of neonatal mouse Purkinje cells exhibit fast gating kinetics and are inhibited by mGluR1 activation.
J. Neurosci., 2013 Oct 16 , 33 (16729-40).

378

Meng J et al. Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization.
Eur. J. Pharmacol., 2013 Oct 15 , 718 (87-97).

379

Hasegawa K et al. A Novel KCNQ1 Missense Mutation Identified in a Patient with Juvenile-Onset Atrial Fibrillation Causes Constitutively Open IKs Channels.
Heart Rhythm, 2013 Oct 1 , ().

380

Cuneo BF et al. Arrhythmia phenotype during fetal life suggests long-QT syndrome genotype: risk stratification of perinatal long-QT syndrome.
Circ Arrhythm Electrophysiol, 2013 Oct , 6 (946-51).

381

Orts DJ et al. BcsTx3 is a founder of a novel sea anemone toxin family of potassium channel blocker.
FEBS J., 2013 Oct , 280 (4839-52).

382

Andreasen L et al. Genetic Modifier of the QTc Interval Associated With Early-Onset Atrial Fibrillation.
Can J Cardiol, 2013 Oct , 29 (1234-40).

383

Yoshinaga M et al. Electrocardiographic screening of 1-month-old infants for identifying prolonged QT intervals.
Circ Arrhythm Electrophysiol, 2013 Oct , 6 (932-8).

384

Gianulis EC et al. Direct interaction of eag domains and cyclic nucleotide-binding homology domains regulate deactivation gating in hERG channels.
J. Gen. Physiol., 2013 Oct , 142 (351-66).

385

Fiore A et al. Characterization of hERG1 channel role in mouse colorectal carcinogenesis.
Cancer Med, 2013 Oct , 2 (583-94).

386

Salyer SA et al. Vacuolar ATPase driven potassium transport in highly metastatic breast cancer cells.
Biochim. Biophys. Acta, 2013 Oct , 1832 (1734-43).

387

Lee YS et al. Long QT syndrome: a Korean single center study.
J. Korean Med. Sci., 2013 Oct , 28 (1454-60).

388

Bodi I et al. Differential effects of the β-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels.
J. Cardiovasc. Electrophysiol., 2013 Oct , 24 (1163-71).

389

Kamei S et al. Molecular analysis of potassium ion channel genes in sudden death cases among patients administered psychotropic drug therapy: are polymorphisms in LQT genes a potential risk factor?
J. Hum. Genet., 2013 Nov 28 , ().

390

Nogawa H et al. Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs.
Eur. J. Pharmacol., 2013 Nov 15 , 720 (29-37).

391

Friddin MS et al. Single-channel electrophysiology of cell-free expressed ion channels by direct incorporation in lipid bilayers.
Analyst, 2013 Nov 12 , 138 (7294-8).

392

Stump MR et al. LQT2 nonsense mutations generate trafficking defective NH2-terminally truncated channels by the reinitiation of translation.
Am. J. Physiol. Heart Circ. Physiol., 2013 Nov 1 , 305 (H1397-404).

393

Ayon RJ et al. Mutant hERG channel traffic jam. Focus on "Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum".
Am. J. Physiol., Cell Physiol., 2013 Nov 1 , 305 (C916-8).

394

Smith JL et al. Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.
Am. J. Physiol., Cell Physiol., 2013 Nov 1 , 305 (C919-30).

395

Tang H et al. Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.
Bioorg. Med. Chem. Lett., 2013 Nov 1 , 23 (5829-32).

396

Coi A et al. Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.
J. Mol. Graph. Model., 2013 Nov , 46 (93-104).

397

Almilaji A et al. AMP-activated protein kinase regulates hERG potassium channel.
Pflugers Arch., 2013 Nov , 465 (1573-82).

398

Oshima A et al. Reconstitution of human ether-a-go-go-related gene channels in microfabricated silicon chips.
Anal. Chem., 2013 May 7 , 85 (4363-9).

399

Lamothe SM et al. The serum- and glucocorticoid-inducible kinases SGK1 and SGK3 regulate hERG channel expression via ubiquitin ligase Nedd4-2 and GTPase Rab11.
J. Biol. Chem., 2013 May 24 , 288 (15075-84).

400

Koenig X et al. Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile.
Toxicol. Appl. Pharmacol., 2013 May 22 , ().

401

Doherty KR et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Toxicol. Appl. Pharmacol., 2013 May 21 , ().

402

Leanza L et al. Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines.
Curr. Pharm. Des., 2013 May 16 , ().

403

Mitton-Fry MJ et al. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Bioorg. Med. Chem. Lett., 2013 May 15 , 23 (2955-61).

404

Leifert A et al. Differential hERG ion channel activity of ultrasmall gold nanoparticles.
Proc. Natl. Acad. Sci. U.S.A., 2013 May 14 , 110 (8004-9).

405

de la Peña P et al. Mapping of interactions between the N- and C-termini and the channel core in HERG K+ channels.
Biochem. J., 2013 May 1 , 451 (463-74).

406

Andaloussi M et al. A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787.
Bioorg. Med. Chem. Lett., 2013 May 1 , 23 (2663-70).

407

Carr DB et al. Effects of injectable HPβCD-diclofenac on the human delayed rectifier potassium channel current in vitro and on proarrhythmic QTc in vivo.
Clin Ther, 2013 May , 35 (646-58).

408

An HS et al. Sudden cardiac arrest during anesthesia in a 30-month-old boy with syndactyly: a case of genetically proven Timothy syndrome.
J. Korean Med. Sci., 2013 May , 28 (788-91).

409

McBride CM et al. Mechanistic basis for type 2 long QT syndrome caused by KCNH2 mutations that disrupt conserved arginine residues in the voltage sensor.
J. Membr. Biol., 2013 May , 246 (355-64).

410

Wei X et al. ZC88, a novel 4-amino piperidine analog, inhibits the growth of neuroblastoma cells through blocking hERG potassium channel.
Cancer Biol. Ther., 2013 May , 14 (450-7).

411

Aziz PF et al. Do LQTS gene single nucleotide polymorphisms alter QTc intervals at rest and during exercise stress testing?
Ann Noninvasive Electrocardiol, 2013 May , 18 (288-93).

412

Matsa E et al. Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes.
Eur. Heart J., 2013 Mar 6 , ().

413

Guo B et al. Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.
J. Med. Chem., 2013 Mar 28 , 56 (2642-50).

414

Park JE et al. Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers.
Bioorg. Med. Chem. Lett., 2013 Mar 15 , 23 (1887-90).

415

Long Y et al. Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride.
Toxicol. Appl. Pharmacol., 2013 Mar 1 , 267 (155-66).

416

Babcock JJ et al. hERG channel function: beyond long QT.
Acta Pharmacol. Sin., 2013 Mar , 34 (329-35).

417

Hashimoto R et al. The KCNH2 gene is associated with neurocognition and the risk of schizophrenia.
World J. Biol. Psychiatry, 2013 Mar , 14 (114-20).

418

Moorthy NS et al. QSAR and pharmacophore analysis of a series of piperidinyl urea derivatives as HERG blockers and H3 antagonists.
Curr Drug Discov Technol, 2013 Mar , 10 (47-58).

419

Orts DJ et al. Biochemical and electrophysiological characterization of two sea anemone type 1 potassium toxins from a geographically distant population of Bunodosoma caissarum.
Mar Drugs, 2013 Mar , 11 (655-79).

420

Jehle J et al. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
Br. J. Pharmacol., 2013 Mar , 168 (1215-29).

421

Munoz C et al. Klotho sensitivity of the hERG channel.
FEBS Lett., 2013 Jun 5 , 587 (1663-8).

422

Steinke K et al. Coxsackievirus B3 modulates cardiac ion channels.
FASEB J., 2013 Jun 27 , ().

423

Colenso CK et al. Interactions between voltage sensor and pore domains in a hERG K+ channel model from molecular simulations and the effects of a voltage sensor mutation.
J Chem Inf Model, 2013 Jun 24 , 53 (1358-70).

424

Chen Y et al. Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.
J. Med. Chem., 2013 Jun 13 , 56 (4671-90).

425

Ginman T et al. Core refinement toward permeable β-secretase (BACE-1) inhibitors with low hERG activity.
J. Med. Chem., 2013 Jun 13 , 56 (4181-205).

426

Byeon SR et al. Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer's disease treatment.
Bioorg. Med. Chem. Lett., 2013 Jun 1 , 23 (3467-9).

427

Wang S et al. Recent developments in computational prediction of HERG blockage.
Curr Top Med Chem, 2013 Jun 1 , 13 (1317-26).

428

Santos Y et al. Arrhythmogenic effect of a crude extract from sea anemone Condylactis gigantea: possible involvement of rErg1 channels.
Toxicon, 2013 Jun 1 , 67 (47-54).

429

Townsend C et al. Predicting Drug-Induced QT Prolongation and Torsades de Pointes: A Review of Preclinical Endpoint Measures.
Curr Protoc Pharmacol, 2013 Jun , Chapter 10 (Unit10.16).

430

Gravel AE et al. An NMR investigation of the structure, function and role of the hERG channel selectivity filter in the long QT syndrome.
Biochim. Biophys. Acta, 2013 Jun , 1828 (1494-502).

431

Brudeli B et al. Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist.
Eur J Med Chem, 2013 Jun , 64 (629-37).

432

Lin K et al. Allocryptopine and benzyltetrahydropalmatine block hERG potassium channels expressed in HEK293 cells.
Acta Pharmacol. Sin., 2013 Jun , 34 (847-58).

433

Stowasser M Primary aldosteronism and potassium channel mutations.
Curr Opin Endocrinol Diabetes Obes, 2013 Jun , 20 (170-9).

434

Lahtinen AM et al. Prevalence of arrhythmia-associated gene mutations and risk of sudden cardiac death in the Finnish population.
Ann. Med., 2013 Jun , 45 (328-35).

435

Kazmierczak M et al. External pH modulates EAG superfamily K+ channels through EAG-specific acidic residues in the voltage sensor.
J. Gen. Physiol., 2013 Jun , 141 (721-35).

436

Arcangeli A et al. High hERG1 expression in advanced melanoma.
Melanoma Res., 2013 Jun , 23 (185-90).

437

Brelidze TI et al. Structure of the C-terminal region of an ERG channel and functional implications.
Proc. Natl. Acad. Sci. U.S.A., 2013 Jul 9 , 110 (11648-53).

438

Nilsson MF et al. Comparative effects of sodium channel blockers in short term rat whole embryo culture.
Toxicol. Appl. Pharmacol., 2013 Jul 8 , ().

439

Cui Z et al. Regulation of the human ether-a-go-go-related gene (hERG) channel by Rab4 protein through neural precursor cell-expressed developmentally down-regulated protein 4-2 (Nedd4-2).
J. Biol. Chem., 2013 Jul 26 , 288 (21876-86).

440

Kiss T et al. Identification of diterpene alkaloids from Aconitum napellus subsp. firmum and GIRK channel activities of some Aconitum alkaloids.
Fitoterapia, 2013 Jul 19 , ().

441

Duchatelet S et al. Identification of a KCNQ1 Polymorphism Acting as a Protective Modifier against Arrhythmic Risk in Long QT Syndrome.
Circ Cardiovasc Genet, 2013 Jul 15 , ().

442

Seki M et al. Synthesis and biological evaluation of pyrrolidine derivatives as novel and potent sodium channel blockers for the treatment of ischemic stroke.
Bioorg. Med. Chem. Lett., 2013 Jul 15 , 23 (4230-4).

443

Ryu S et al. The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Bioorg. Med. Chem. Lett., 2013 Jul 1 , 23 (3848-51).

444

Takanari H et al. Efficient and specific cardiac IK1 inhibition by a new pentamidine analogue.
Cardiovasc. Res., 2013 Jul 1 , 99 (203-14).

445

Varkevisser R et al. Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue.
Br. J. Pharmacol., 2013 Jul , 169 (1322-34).

446

Son MK et al. Genetic mutation in korean patients of sudden cardiac arrest as a surrogating marker of idiopathic ventricular arrhythmia.
J. Korean Med. Sci., 2013 Jul , 28 (1021-6).

447

Lieve KV et al. Results of genetic testing in 855 consecutive unrelated patients referred for long QT syndrome in a clinical laboratory.
Genet Test Mol Biomarkers, 2013 Jul , 17 (553-61).

448

Rayan A et al. Indexing molecules for their hERG liability.
Eur J Med Chem, 2013 Jul , 65 (304-14).

449

Jou CJ et al. An In Vivo Cardiac Assay to Determine the Functional Consequences of Putative Long QT Syndrome Mutations.
Circ. Res., 2013 Jan 9 , ().

450

Ford J et al. Human Electrophysiological and Pharmacological Properties of XEN-D0101: A Novel Atrial Selective Kv1.5/IKur Inhibitor.
J. Cardiovasc. Pharmacol., 2013 Jan 29 , ().

451

Di Martino GP et al. An automated docking protocol for hERG channel blockers.
J Chem Inf Model, 2013 Jan 28 , 53 (159-75).

452

Li H et al. The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.
Bioorg. Med. Chem. Lett., 2013 Jan 15 , 23 (466-71).

453

Di Veroli GY et al. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Am. J. Physiol. Heart Circ. Physiol., 2013 Jan 1 , 304 (H104-17).

454

Zhang Y et al. Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression.
Biochem. Pharmacol., 2013 Jan 1 , 85 (59-68).

455

Narayana Moorthy NS et al. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
Curr Drug Targets, 2013 Jan 1 , 14 (102-13).

456

Liu L et al. A novel mutation in the transmembrane nonpore region of the KCNH2 gene causes severe clinical manifestations of long QT syndrome.
Heart Rhythm, 2013 Jan , 10 (61-7).

457

Zarzoso M et al. Mission possible: RNA interference rescues the hERG current.
Heart Rhythm, 2013 Jan , 10 (137-8).

458

Beattie DT et al. An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954.
Vascul. Pharmacol., 2013 Jan , 58 (150-6).

459

Lu X et al. RNA interference targeting E637K mutation rescues hERG channel currents and restores its kinetic properties.
Heart Rhythm, 2013 Jan , 10 (128-36).

460

Braam SR et al. Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes.
Stem Cell Res, 2013 Jan , 10 (48-56).

461

Ng CA et al. Insights into hERG K+ channel structure and function from NMR studies.
Eur. Biophys. J., 2013 Jan , 42 (71-9).

462

Wei T et al. [Effect of berberine, liensinine and neferine on HERG channel expression].
Zhongguo Zhong Yao Za Zhi, 2013 Jan , 38 (239-44).

463

Zhang A et al. L539 fs/47, a truncated mutation of human ether-a-go-go-related gene (hERG), decreases hERG ion channel currents in HEK 293 cells.
Clin. Exp. Pharmacol. Physiol., 2013 Jan , 40 (28-36).

464

Sirenko O et al. Multiparameter In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using iPSC Cells.
J Biomol Screen, 2013 Jan , 18 (39-53).

465

Terrenoire C et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
J. Gen. Physiol., 2013 Jan , 141 (61-72).

466

Su X et al. Effect of microculture on cell metabolism and biochemistry: do cells get stressed in microchannels?
Anal. Chem., 2013 Feb 5 , 85 (1562-70).

467

Hong HK et al. Block of hERG K+ channel and prolongation of action potential duration by fluphenazine at submicromolar concentration.
Eur. J. Pharmacol., 2013 Feb 28 , 702 (165-73).

468

Andreasen C et al. Mutations in Genes Encoding Cardiac Ion Channels Previously Associated With Sudden Infant Death Syndrome (SIDS) Are Present With High Frequency in New Exome Data.
Can J Cardiol, 2013 Feb 25 , ().

469

Hausammann GJ et al. Generation of an antibody toolbox to characterize hERG.
Biochem. Biophys. Res. Commun., 2013 Feb 1 , 431 (70-5).

470

Harris RA et al. Human metastable epiallele candidates link to common disorders.
Epigenetics, 2013 Feb , 8 (157-63).

471

Yang LJ et al. New targets for the antitumor activity of gambogic acid in hematologic malignancies.
Acta Pharmacol. Sin., 2013 Feb , 34 (191-8).

472

Gustina AS et al. The eag domain regulates hERG channel inactivation gating via a direct interaction.
J. Gen. Physiol., 2013 Feb , 141 (229-41).

473

Dong H et al. Functional expression of ERG1 potassium channels in rat alveolar macrophages.
J. Mol. Histol., 2013 Feb , 44 (117-24).

474

Norring SA et al. Channel sialic acids limit hERG channel activity during the ventricular action potential.
FASEB J., 2013 Feb , 27 (622-31).

475

Silva D et al. Novel mutation in the KCNH2 gene associated with long QT syndrome.
Rev Port Cardiol, 2013 Feb , 32 (163-4).

476

Zemzemi N et al. Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials.
Br. J. Pharmacol., 2013 Feb , 168 (718-33).

477

Hausammann GJ et al. Chimeric hERG channels containing a tetramerization domain are functional and stable.
Biochemistry, 2013 Dec 23 , 52 (9237-45).

478

Shi YP et al. External protons destabilize the activated voltage sensor in hERG channels.
Eur. Biophys. J., 2013 Dec 21 , ().

479

Louvel J et al. Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.
J. Med. Chem., 2013 Dec 12 , 56 (9427-40).

480

Bellin M et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.
EMBO J., 2013 Dec 11 , 32 (3161-75).

481

Iwai C et al. Hsp90 prevents interaction between CHIP and HERG proteins to facilitate maturation of wild-type and mutant HERG proteins.
Cardiovasc. Res., 2013 Dec 1 , 100 (520-8).

482

He YL et al. High-quality triplicate electrocardiogram monitoring in a first-in-man study: potential for early detection of drug-induced QT prolongation.
Int J Clin Pharmacol Ther, 2013 Dec , 51 (948-57).

483

Apaja PM et al. Ubiquitination-dependent quality control of hERG K+ channel with acquired and inherited conformational defect at the plasma membrane.
Mol. Biol. Cell, 2013 Dec , 24 (3787-804).

484

Hintsa T et al. Work stress and the long QT syndrome: high job strain and effort-reward imbalance at work associated with arrhythmic risk in the long QT syndrome.
J. Occup. Environ. Med., 2013 Dec , 55 (1387-93).

485

Goineau S et al. In vitro safety cardiovascular pharmacology studies: impact of formulation preparation and analysis.
Regul. Toxicol. Pharmacol., 2013 Dec , 67 (499-505).

486

Lin J et al. [Protein tyrosine phosphatase non-receptor type 12 negatively regulates cardiac HERG channel currents].
Nan Fang Yi Ke Da Xue Xue Bao, 2013 Dec , 33 (1718-22).

487

Fortunato A et al. An analytical method for the quantification of hERG1 channel gene expression in human colorectal cancer.
Diagn. Mol. Pathol., 2013 Dec , 22 (215-21).

488

Dowling JE et al. Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo.
ACS Med Chem Lett, 2013 Aug 8 , 4 (800-5).

489

Kato K et al. Cardiac Channelopathies Associated with Infantile Fatal Ventricular Arrhythmias: From the Cradle to the Bench.
J. Cardiovasc. Electrophysiol., 2013 Aug 26 , ().

490

Hayashi M et al. Molecular basis of potassium channels in pancreatic duct epithelial cells.
Channels (Austin), 2013 Aug 20 , 7 ().

491

Dou Y et al. The neutral, hydrophobic isoleucine at position I521 in the extracellular S4 domain of hERG contributes to channel gating equilibrium.
Am. J. Physiol., Cell Physiol., 2013 Aug 15 , 305 (C468-78).

492

K E Y et al. Trafficking defects in PAS domain mutant Kv11.1 channels: roles of reduced domain stability and altered domain-domain interactions.
Biochem. J., 2013 Aug 15 , 454 (69-77).

493

Sun H et al. Are hERG channel blockers also phospholipidosis inducers?
Bioorg. Med. Chem. Lett., 2013 Aug 15 , 23 (4587-90).

494

Cicek MS et al. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.
Hum. Mol. Genet., 2013 Aug 1 , 22 (3038-47).

495

Kruse M et al. The phosphoinositide sensitivity of the KV channel family.
Channels (Austin), 2013 Aug 1 , 7 ().

496

Partemi S et al. Loss-of-function KCNH2 mutation in a family with long QT syndrome, epilepsy, and sudden death.
Epilepsia, 2013 Aug , 54 (e112-6).

497

Sroubek J et al. Sequence and structure-specific elements of HERG mRNA determine channel synthesis and trafficking efficiency.
FASEB J., 2013 Aug , 27 (3039-53).

498

Gao Y et al. A novel deletion-frameshift mutation in the S1 region of HERG gene in a Chinese family with long QT syndrome.
Chin. Med. J., 2013 Aug , 126 (3093-6).

499

Choi SW et al. Class 3 inhibition of hERG K+ channel by caffeic acid phenethyl ester (CAPE) and curcumin.
Pflugers Arch., 2013 Aug , 465 (1121-34).

500

Harris K et al. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.
Toxicol. Sci., 2013 Aug , 134 (412-26).

501

Arslan Yildiz A et al. Biomimetic membrane platform containing hERG potassium channel and its application to drug screening.
Analyst, 2013 Apr 7 , 138 (2007-12).

502

Perry MD et al. Pore helices play a dynamic role as integrators of domain motion during Kv11.1 channel inactivation gating.
J. Biol. Chem., 2013 Apr 19 , 288 (11482-91).

503

Carvalho JF et al. Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide.
J. Med. Chem., 2013 Apr 11 , 56 (2828-40).

504

Crotti L et al. Long QT syndrome-associated mutations in intrauterine fetal death.
JAMA, 2013 Apr 10 , 309 (1473-82).

505

Wang Z et al. Components of gating charge movement and S4 voltage-sensor exposure during activation of hERG channels.
J. Gen. Physiol., 2013 Apr , 141 (431-43).

506

Shinwari ZM et al. Identification of a novel KCNQ1 mutation in a large Saudi family with long QT syndrome: clinical consequences and preventive implications.
Clin. Genet., 2013 Apr , 83 (370-4).

507

Islas LD The electric heart of hERG.
J. Gen. Physiol., 2013 Apr , 141 (409-11).

508

Yoshikane Y et al. A case of long QT syndrome with triple gene abnormalities: digenic mutations in KCNH2 and SCN5A and gene variant in KCNE1.
Heart Rhythm, 2013 Apr , 10 (600-3).

509

He FZ et al. Current pharmacogenomic studies on hERG potassium channels.
Trends Mol Med, 2013 Apr , 19 (227-38).

510

Adaixo R et al. Structural properties of PAS domains from the KCNH potassium channels.
PLoS ONE, 2013 , 8 (e59265).

511

Abdelhady S et al. Erg channel is critical in controlling cell volume during cell cycle in embryonic stem cells.
PLoS ONE, 2013 , 8 (e72409).

512

Moric-Janiszewska E et al. Quantitative PCR as an Alternative in the Diagnosis of Long-QT Syndrome.
Biomed Res Int, 2013 , 2013 (418604).

513

Ouadid-Ahidouch H et al. K(+) channels and cell cycle progression in tumor cells.
Front Physiol, 2013 , 4 (220).

514

Shimizu W Update of diagnosis and management of inherited cardiac arrhythmias.
Circ. J., 2013 , 77 (2867-72).

515

Ng CA et al. C-Terminal β9-Strand of the Cyclic Nucleotide-Binding Homology Domain Stabilizes Activated States of Kv11.1 Channels.
PLoS ONE, 2013 , 8 (e77032).

516

Springer C et al. A fingerprint pair analysis of hERG inhibition data.
Chem Cent J, 2013 , 7 (167).

517

He F et al. The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China.
PLoS ONE, 2013 , 8 (e61317).

518

Asayama M et al. Effects of an hERG activator, ICA-105574, on electrophysiological properties of canine hearts.
J. Pharmacol. Sci., 2013 , 121 (1-8).

519

Kramer J et al. MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes.
Sci Rep, 2013 , 3 (2100).

520

Kireeva N et al. Towards in silico identification of the human ether-a-go-go-related gene channel blockers: discriminative vs. generative classification models.
SAR QSAR Environ Res, 2013 , 24 (103-17).

521

Sampson HM et al. Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines.
Orphanet J Rare Dis, 2013 , 8 (11).

522

Zhao X et al. Ginkgo biloba extract and ginkgolide antiarrhythmic potential by targeting hERG and ICa-L channel.
J. Pharmacol. Sci., 2013 , 123 (318-27).

523

Bethge N et al. Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma.
PLoS ONE, 2013 , 8 (e79602).

524

Mehnert JM et al. Electrophysiological characterization of spontaneously contracting cell aggregates obtained from rainbow trout larvae with multielectrode arrays.
Cell. Physiol. Biochem., 2013 , 32 (1374-85).

525

Shu L et al. Modulation of HERG K+ channels by chronic exposure to activators and inhibitors of PKA and PKC: actions independent of PKA and PKC phosphorylation.
Cell. Physiol. Biochem., 2013 , 32 (1830-44).

526

Karnik R et al. Endocytosis of HERG is clathrin-independent and involves arf6.
PLoS ONE, 2013 , 8 (e85630).

527

Pérez Riera AR et al. Congenital short QT syndrome: landmarks of the newest arrhythmogenic cardiac channelopathy.
Cardiol J, 2013 , 20 (464-71).

528

Okata S et al. The generation of induced pluripotent stem cells from a patient with KCNH2 G603D, without LQT2 disease associated symptom.
J. Med. Dent. Sci., 2013 , 60 (17-22).

529

Ranjan AP et al. Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation.
J Nanobiotechnology, 2013 , 11 (40).

530

Li G et al. A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells.
Int J Nanomedicine, 2013 , 8 (1293-306).

531

Thai KM et al. Pharmacophore modeling for antitargets.
Curr Top Med Chem, 2013 , 13 (1002-14).

532

Trolle C et al. Long QT interval in Turner syndrome--a high prevalence of LQTS gene mutations.
PLoS ONE, 2013 , 8 (e69614).

533

Babcock JJ et al. Integrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitors.
PLoS ONE, 2013 , 8 (e69513).

534

Pakladok T et al. PIKfyve sensitivity of hERG channels.
Cell. Physiol. Biochem., 2013 , 31 (785-94).

535

Lansu K et al. Potassium channel activation inhibits proliferation of breast cancer cells by activating a senescence program.
Cell Death Dis, 2013 , 4 (e652).

536

Crociani O et al. hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer.
Sci Rep, 2013 , 3 (3308).

537

Mi Y et al. The role of potassium channel activation in celecoxib-induced analgesic action.
PLoS ONE, 2013 , 8 (e54797).

538

Andrsova I et al. Clinical characteristics of 30 Czech families with long QT syndrome and KCNQ1 and KCNH2 gene mutations: importance of exercise testing.
J Electrocardiol, 2012 Nov-Dec , 45 (746-51).

539

Ildarova R et al. Sodium-channel blockers might contribute to the prevention of ventricular tachycardia in patients with long QT syndrome type 2: a description of 4 cases.
J Electrocardiol, 2012 May-Jun , 45 (237-43).

540

[Three-dimensional structure of human Kv10.2 ion channel studied by single particle electron microscopy and molecular modeling].
Bioorg. Khim., 2012 Mar-Apr , 38 (177-84).

541

Zhao Y et al. Transfection by eukaryotic expression vector pcDNA3-HERG inhibits the cultured neonatal rabbit ventricular myocyte hypertrophy induced by phenylephrine.
Cardiovasc. Pathol., 2012 Jul-Aug , 21 (339-45).

542

Liu Q et al. Effect of daurisoline on HERG channel electrophysiological function and protein expression.
J. Nat. Prod., 2012 Sep 28 , 75 (1539-45).

543

Guo J et al. Cell surface expression of human ether-a-go-go-related gene (hERG) channels is regulated by caveolin-3 protein via the ubiquitin ligase Nedd4-2.
J. Biol. Chem., 2012 Sep 28 , 287 (33132-41).

544

Jindal HK et al. Proteomic analyses of transgenic LQT1 and LQT2 rabbit hearts elucidate an increase in expression and activity of energy producing enzymes.
J Proteomics, 2012 Sep 18 , 75 (5254-65).

545

Mattmann ME et al. Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.
Bioorg. Med. Chem. Lett., 2012 Sep 15 , 22 (5936-41).

546

Dossetter AG et al. Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.
Bioorg. Med. Chem. Lett., 2012 Sep 1 , 22 (5563-8).

547

Tan PS et al. Voltage-sensing domain mode shift is coupled to the activation gate by the N-terminal tail of hERG channels.
J. Gen. Physiol., 2012 Sep , 140 (293-306).

548

Zumhagen S et al. Inherited long QT syndrome: clinical manifestation, genetic diagnostics, and therapy.
Herzschrittmacherther Elektrophysiol, 2012 Sep , 23 (211-9).

549

Garg V et al. Tuning of EAG K(+) channel inactivation: molecular determinants of amplification by mutations and a small molecule.
J. Gen. Physiol., 2012 Sep , 140 (307-24).

550

Annedi SC et al. Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine.
Eur J Med Chem, 2012 Sep , 55 (94-107).

551

Kapoor A et al. Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.
Antimicrob. Agents Chemother., 2012 Sep , 56 (4891-9).

552

Jonsson MK et al. Deciphering hERG channels: molecular basis of the rapid component of the delayed rectifier potassium current.
J. Mol. Cell. Cardiol., 2012 Sep , 53 (369-74).

553

Bhattarai D et al. Synthesis and in vitro antibacterial activity of novel 3-azabicyclo[3.3.0]octanyl oxazolidinones.
Chem Biol Drug Des, 2012 Sep , 80 (388-97).

554

Lee SH et al. Blockade of human HERG K⁺ channels by rosiglitazone, an antidiabetic drug.
Arch. Pharm. Res., 2012 Sep , 35 (1655-64).

555

Quail T et al. Chaotic dynamics in cardiac aggregates induced by potassium channel block.
Chaos, 2012 Sep , 22 (033140).

556

Cid JM et al. Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor.
J. Med. Chem., 2012 Oct 25 , 55 (8770-89).

557

Durdagi S et al. Modeling of open, closed, and open-inactivated states of the hERG1 channel: structural mechanisms of the state-dependent drug binding.
J Chem Inf Model, 2012 Oct 22 , 52 (2760-74).

558

Abderemane-Ali F et al. Dual effect of phosphatidyl (4,5)-bisphosphate PIP2 on Shaker K+ channels.
J. Biol. Chem., 2012 Oct 19 , 287 (36158-67).

559

Procopiou PA et al. Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.
Bioorg. Med. Chem., 2012 Oct 15 , 20 (6097-108).

560

Giudicessi JR et al. Phylogenetic and physicochemical analyses enhance the classification of rare nonsynonymous single nucleotide variants in type 1 and 2 long-QT syndrome.
Circ Cardiovasc Genet, 2012 Oct 1 , 5 (519-28).

561

Chu W et al. Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome.
Cardiovasc. Res., 2012 Oct 1 , 96 (90-8).

562

Högberg T et al. Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment?
Bioorg. Med. Chem. Lett., 2012 Oct 1 , 22 (6039-47).

563

Khalaf AI et al. Design, synthesis and antibacterial activity of minor groove binders: the role of non-cationic tail groups.
Eur J Med Chem, 2012 Oct , 56 (39-47).

564

Asghar MY et al. Sphingosine 1-phosphate and human ether-a'-go-go-related gene potassium channels modulate migration in human anaplastic thyroid cancer cells.
Endocr. Relat. Cancer, 2012 Oct , 19 (667-80).

565

Lee HA et al. Wide spectrum of inhibitory effects of sertraline on cardiac ion channels.
Korean J. Physiol. Pharmacol., 2012 Oct , 16 (327-32).

566

Winkel BG et al. The prevalence of mutations in KCNQ1, KCNH2, and SCN5A in an unselected national cohort of young sudden unexplained death cases.
J. Cardiovasc. Electrophysiol., 2012 Oct , 23 (1092-8).

567

Wiśniowska B et al. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
J Appl Toxicol, 2012 Oct , 32 (858-66).

568

Wen D et al. Validation of visualized transgenic zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk candidates.
J Appl Toxicol, 2012 Oct , 32 (834-42).

569

Zhao QH et al. [KCNQ1, KCNH2, KCNE1 and KCNE2 potassium channels gene variants in sudden manhood death syndrome].
Fa Yi Xue Za Zhi, 2012 Oct , 28 (337-41, 346).

570

Nirogi R et al. Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists.
J. Med. Chem., 2012 Nov 8 , 55 (9255-69).

571

Swahn BM et al. Design and synthesis of β-Site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
J. Med. Chem., 2012 Nov 8 , 55 (9346-61).

572

Dong Q et al. Blocking of the human ether-à-go-go-related gene channel by imatinib mesylate.
Biol. Pharm. Bull., 2012 Nov 30 , ().

573

Sherhod R et al. Automating knowledge discovery for toxicity prediction using jumping emerging pattern mining.
J Chem Inf Model, 2012 Nov 26 , 52 (3074-87).

574

Portonovo SA et al. hERG drug response measured in droplet bilayers.
Biomed Microdevices, 2012 Nov 18 , ().

575

Potet F et al. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
J. Biol. Chem., 2012 Nov 16 , 287 (39613-25).

576

Bahl A et al. The discovery of CCR3/H1 dual antagonists with reduced hERG risk.
Bioorg. Med. Chem. Lett., 2012 Nov 1 , 22 (6688-93).

577

Edelmann J et al. Long QT syndrome mutation detection by SNaPshot technique.
Int. J. Legal Med., 2012 Nov , 126 (969-73).

578

Kinoshita K et al. A novel missense mutation causing a G487R substitution in the S2-S3 loop of human ether-à-go-go-related gene channel.
J. Cardiovasc. Electrophysiol., 2012 Nov , 23 (1246-53).

579

Stump MR et al. Early LQT2 nonsense mutation generates N-terminally truncated hERG channels with altered gating properties by the reinitiation of translation.
J. Mol. Cell. Cardiol., 2012 Nov , 53 (725-33).

580

Kam YL et al. HYP-1, a novel diamide compound, relieves inflammatory and neuropathic pain in rats.
Pharmacol. Biochem. Behav., 2012 Nov , 103 (33-42).

581

Zhang Y et al. hERG ion channel pharmacology: cell membrane liposomes in porous-supported lipid bilayers compared with whole-cell patch-clamping.
Eur. Biophys. J., 2012 Nov , 41 (949-58).

582

Xie S et al. Identification of a new specific Kv1.3 channel blocker, Ctri9577, from the scorpion Chaerilus tricostatus.
, 2012 May 8 , ().

583

Donovan AJ et al. LQT2 Mutation on the Kv11.1 Ion Channel Inhibits Current Activity by Ablating a PKCα Consensus Site.
, 2012 May 31 , ().

584

Du YM et al. 18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels.
, 2012 May 21 , ().

585

Skidmore J et al. Identification of a series of 1,3,4-oxadiazol-2-amines as potent alpha-7 agonists with efficacy in the novel object recognition model of cognition.
Bioorg. Med. Chem. Lett., 2012 May 15 , 22 (3560-3).

586

Kasai S et al. Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3-aminomethylquinolines: reducing human ether-a-go-go-related gene (hERG) associated liabilities.
J. Med. Chem., 2012 May 10 , 55 (4336-51).

587

Tang H et al. Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.
ACS Med Chem Lett, 2012 May 10 , 3 (367-72).

588

Chen J et al. Binding interface of cardiac potassium channel proteins identified by hydrogen deuterium exchange of synthetic peptides.
Anal Bioanal Chem, 2012 May , 403 (1303-9).

589

Jiménez-Vargas JM et al. Interacting sites of scorpion toxin ErgTx1 with hERG1 K+ channels.
Toxicon, 2012 May , 59 (633-41).

590

Boström J et al. Oxadiazoles in medicinal chemistry.
J. Med. Chem., 2012 Mar 8 , 55 (1817-30).

591

Skerlj R et al. Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.
ACS Med Chem Lett, 2012 Mar 8 , 3 (216-21).

592

Wacker SJ et al. Identification of Selective Inhibitors of the Potassium Channel Kv1.1-1.2((3)) by High-Throughput Virtual Screening and Automated Patch Clamp.
, 2012 Mar 30 , ().

593

Menéndez ST et al. Role of HERG1 potassium channel in both malignant transformation and disease progression in head and neck carcinomas.
, 2012 Mar 30 , ().

594

Ramnauth J et al. 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors: lead optimization studies resulting in the identification of N-(1-(2-(methylamino)ethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide as a p
J. Med. Chem., 2012 Mar 22 , 55 (2882-93).

595

Hanrahan P et al. Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity.
Bioorg. Med. Chem. Lett., 2012 Mar 15 , 22 (2271-8).

596

Liu GX et al. Differential conditions for early after-depolarizations and triggered activity in cardiomyocytes derived from transgenic LQT1 and LQT2 rabbits.
J. Physiol. (Lond.), 2012 Mar 1 , 590 (1171-80).

597

Bregman H et al. The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SAR.
Bioorg. Med. Chem. Lett., 2012 Mar 1 , 22 (2033-42).

598

Chakka N et al. Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Na(v)1.7 antagonists.
Bioorg. Med. Chem. Lett., 2012 Mar 1 , 22 (2052-62).

599

Lacombe P et al. 3,4-Diarylpiperidines as potent renin inhibitors.
Bioorg. Med. Chem. Lett., 2012 Mar 1 , 22 (1953-7).

600

Moorthy NS et al. Structural analysis of 2-piperidin-4-yl-actamide derivatives for hERG blocking and MCH R1 antagonistic activities.
Curr Drug Discov Technol, 2012 Mar , 9 (25-38).

601

Zhao XY et al. Frequency- and state-dependent blockade of human ether-a-go-go-related gene K+ channel by arecoline hydrobromide.
Chin. Med. J., 2012 Mar , 125 (1068-75).

602

Kaddar N et al. Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr.
J. Cardiovasc. Pharmacol. Ther., 2012 Mar , 17 (102-9).

603

Tan Y et al. Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.
J Mol Model, 2012 Mar , 18 (1023-36).

604

Peterson LB et al. The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking.
Mol. Pharm., 2012 Jun 4 , 9 (1841-6).

605

Gunnström M et al. Antipsychotic drugs cause bradycardia in GD 13 rat embryos in vitro.
, 2012 Jun 28 , ().

606

Su BH et al. Predictive toxicology modeling: protocols for exploring hERG classification and Tetrahymena pyriformis end point predictions.
J Chem Inf Model, 2012 Jun 25 , 52 (1660-73).

607

Pérez-Victoria I et al. Isolation and structural elucidation of cyclic tetrapeptides from Onychocola sclerotica.
J. Nat. Prod., 2012 Jun 22 , 75 (1210-4).

608

Carosati E et al. 1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story so Far And Perspectives (Part 2): Action in Other Targets and Antitargets.
, 2012 Jun 18 , ().

609

Cumming JG et al. The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.
Bioorg. Med. Chem. Lett., 2012 Jun 15 , 22 (3895-9).

610

Pajouhesh H et al. Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.
Bioorg. Med. Chem. Lett., 2012 Jun 15 , 22 (4153-8).

611

Mihalic JT et al. Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition.
Bioorg. Med. Chem. Lett., 2012 Jun 1 , 22 (3781-5).

612

Zhao J et al. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels.
J Ethnopharmacol, 2012 Jun 1 , 141 (685-91).

613

Guo J et al. A422T mutation in HERG potassium channel retained in ER is rescurable by pharmacologic or molecular chaperones.
Biochem. Biophys. Res. Commun., 2012 Jun 1 , 422 (305-10).

614

Van Slyke AC et al. Proton block of the pore underlies the inhibition of hERG cardiac K+ channels during acidosis.
Am. J. Physiol., Cell Physiol., 2012 Jun , 302 (C1797-806).